

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)

Gastric Cancer

(Including cancer in the proximal 5cm of the stomach)

Version 1.2011

NCCN.org

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines™ Version 1.2011 Panel Members

Gastric Cancer

[NCCN Guidelines Index](#)
[Gastric Cancer Table of Contents](#)
[Discussion](#)

* Jaffer A. Ajani, MD/Chair † ▫
The University of Texas
MD Anderson Cancer Center

James S. Barthel, MD ▫ ▯
H. Lee Moffitt Cancer Center
& Research Institute

David J. Bentrem, MD ¶
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Thomas A. D'Amico, MD ¶
Duke Cancer Institute

Prajan Das, MD, MS, MPH §
The University of Texas
MD Anderson Cancer Center

Crystal Denlinger, MD †
Fox Chase Cancer Center

Charles S. Fuchs, MD, MPH †
Dana-Farber/Brigham and Women's Cancer
Center

Hans Gerdes, MD ▫ ▯
Memorial Sloan-Kettering Cancer Center

Robert E. Glasgow, MD ¶
Huntsman Cancer Institute
at the University of Utah

James A. Hayman, MD, MBA §
University of Michigan
Comprehensive Cancer Center

NCCN
Lauren Gallagher, RPh, PhD
Nicole McMillian, MS
Hema Sundar, PhD

Wayne L. Hofstetter, MD ¶
The University of Texas
MD Anderson Cancer Center

David H. Ilson, MD, PhD † ▯
Memorial Sloan-Kettering Cancer Center

Rajesh N. Keswani, MD ▫
Robert H. Lurie Comprehensive
Cancer Center of Northwestern University

Lawrence R. Kleinberg, MD §
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Michael Korn, MD
UCSF Helen Diller Family
Comprehensive Cancer Center

A. Craig Lockhart, MD, MHS †
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University
School of Medicine

Mary F. Mulcahy, MD ‡
Robert H. Lurie Comprehensive
Cancer Center of Northwestern University

Mark B. Orringer, MD ¶
University of Michigan
Comprehensive Cancer Center

Raymond U. Osarogiagbon, MD † ▯ ‡
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

James A. Posey, MD †
University of Alabama at Birmingham
Comprehensive Cancer Center

Aaron R. Sasson, MD ¶
UNMC Eppley Cancer Center at
The Nebraska Medical Center

Walter J. Scott, MD ¶
Fox Chase Cancer Center

Stephen Shibata, MD †
City of Hope Comprehensive Cancer Center

Vivian E. M. Strong, MD ¶
Memorial Sloan-Kettering Cancer Center

Thomas K. Varghese, Jr, MD ¶
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Graham Warren, MD, PhD
Roswell Park Cancer Institute

Mary Kay Washington, MD, PhD ≠
Vanderbilt-Ingram Cancer Center

Christopher Willett, MD §
Duke Cancer Institute

Cameron D. Wright, MD ¶
Massachusetts General Hospital

† Medical oncology
▫ Gastroenterology
¶ Surgery/Surgical oncology
▯ Internal medicine
§ Radiotherapy/Radiation oncology
‡ Hematology/Hematology oncology
≠ Pathology
* Writing committee member

Continue

[NCCN Guidelines Panel Disclosures](#)

Principles of Systemic Therapy

Mary F. Mulcahy, MD ‡/Lead
Robert H. Lurie Comprehensive
Cancer Center of Northwestern
University

Jaffer A. Ajani, MD/Chair † ▫
The University of Texas
MD Anderson Cancer Center

Crystal Denlinger, MD †
Fox Chase Cancer Center

David H. Ilson, MD, PhD † ▽
Memorial Sloan-Kettering Cancer Center

A. Craig Lockhart, MD, MHS †
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University
School of Medicine

Raymond U. Osarogiagbon, MD † ▽ ‡
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

Principles of Radiation Therapy

Lawrence R. Kleinberg, MD §/Lead
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Prajnan Das, MD, MS, MPH §
The University of Texas
MD Anderson Cancer Center

James A. Hayman, MD, MBA §
University of Michigan
Comprehensive Cancer Center

Christopher Willett, MD §
Duke Cancer Institute

Principles of Surgery

Aaron R. Sasson, MD ¶/Lead
UNMC Eppley Cancer Center at
The Nebraska Medical Center

David J. Bentrem, MD ¶
Robert H. Lurie Comprehensive
Cancer Center of Northwestern
University

Robert E. Glasgow, MD ¶
Huntsman Cancer Institute
at the University of Utah

Vivian E. M. Strong, MD ¶
Memorial Sloan-Kettering Cancer
Center

Principles of Best Supportive Care

James S. Barthel, MD ▫ ▽/Lead
H. Lee Moffitt Cancer Center
& Research Institute

Hans Gerdes, MD ▫ ▽
Memorial Sloan-Kettering Cancer Center

Rajesh N. Keswani, MD ▫
Robert H. Lurie Comprehensive
Cancer Center of Northwestern University

Mary F. Mulcahy, MD ‡
Robert H. Lurie Comprehensive
Cancer Center of Northwestern University

Principles of Pathologic Review and HER2-neu Testing

Mary Kay Washington, MD, PhD ≠
Vanderbilt-Ingram Cancer Center

Principles of Endoscopic Staging and Therapy

Hans Gerdes, MD ▫ ▽/Lead
Memorial Sloan-Kettering Cancer Center

James S. Barthel, MD ▫ ▽
H. Lee Moffitt Cancer Center &
Research Institute

Rajesh N. Keswani, MD ▫
Robert H. Lurie Comprehensive
Cancer Center of Northwestern University

Continue

▫ Gastroenterology
¶ Surgery/Surgical oncology
▽ Internal medicine
§ Radiotherapy/Radiation oncology
‡ Hematology/Hematology oncology
≠ Writing committee member

[NCCN Gastric Cancer Guidelines Panel Members](#)

[NCCN Gastric Cancer Guidelines Sub-Committee Members](#)

[Summary of the Guidelines Updates](#)

[Workup and Evaluation \(GAST-1\)](#)

[Postlaparoscopy Staging and Treatment \(GAST-2\)](#)

[Surgical Outcomes For Patients Who Have Not Received Preoperative Therapy \(GAST-3\)](#)

[Surgical Outcomes For Patients Who Have Received Preoperative Therapy \(GAST-4\)](#)

[Adjuvant Treatment \(GAST-5\)](#)

[Follow-up and Palliative Therapy \(GAST-6\)](#)

[Principles of Endoscopic Staging and Therapy \(GAST-A\)](#)

[Principles of Pathologic Review and HER2-neu Testing \(GAST-B\)](#)

[Principles of Multidisciplinary Team Approach \(GAST-C\)](#)

[Principles of Surgery \(GAST-D\)](#)

[Principles of Systemic Therapy \(GAST-E\)](#)

[Principles of Radiation Therapy \(GAST-F\)](#)

[Principles of Best Supportive Care \(GAST-G\)](#)

[Staging \(ST-1\)](#)

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

The NCCN Guidelines™ for Gastric Cancer includes cancer in the proximal 5cm of the stomach.

The NCCN Guidelines™ are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2011.

**Updates in Version 1.2011 of the NCCN Guidelines from Version 2.2010 include:****Global changes:**

- The algorithms and staging tables were updated to reflect the 7th edition (2010) of the AJCC Staging Manual ([ST-1](#)) and ([ST-2](#)).
- Principles of Endoscopic Staging and Therapy ([GAST-A](#)) is a new page that provides specific endoscopic recommendations for diagnosis, staging, treatment, and post-treatment surveillance for gastric cancer.
- Principles of Pathologic Review and HER2-neu Testing ([GAST-B](#)) is a new page that provides specific recommendations for analysis/interpretation/reporting of pathology results, assessment of treatment response, and assessment of overexpression of HER2-neu.

[GAST-1:](#)

- The Workup section was revised including:
 - ▶ Esophagogastroduodenoscopy changed to “Upper GI endoscopy **and biopsy**”. “HER2-neu testing if metastatic disease is documented/suspected” and “Biopsy confirmation of suspected metastatic disease” are new bullets.
 - ▶ The following bullets were deleted: “H.pylori test, if patient symptomatic from H.pylori, then treat” and “Multidisciplinary evaluation”.

[GAST-2:](#)

- Primary Treatment for patients with M0 disease who are Medically fit, unresectable or Medically unfit: Taxane-based chemoradiation was added as option in addition to fluoropyrimidine-based chemoradiation.

[GAST-3:](#)

- This is a new algorithm that provides surgical outcomes after esophagectomy/clinical pathologic findings and recommendations for patients who have not received preoperative therapy”.

[GAST-4:](#)

- Postoperative Treatment:
 - ▶ Taxane-based chemoradiation was added as an option in addition to fluoropyrimidine-based chemoradiation.
 - ▶ ECF modifications was added as a treatment option following R0 resection.

[GAST-5:](#)

- The pathways “Complete or major response” changed to “Resectable” and the pathway “Residual, unresectable locoregional and/or metastatic disease” changed to “Unresectable and/or metastatic disease”.

[GAST-5---continued](#)

- Adjunctive Treatment: “Surgery, if appropriate” changed to “Surgery (**preferred**), if appropriate”.

[GAST-6:](#)

- Follow-up:
 - ▶ H&P changed from “every 3-6 mo for 1-3 y, every 6 mo for 3-5 y...” to “every 3-6 mo for 1-2 y, every 6-12 mo for 3-5 y...”
 - ▶ “Monitor for vitamin B₁₂ deficiency...” changed to “Monitor for **nutritional** deficiency...”
 - ▶ “Confirm that HER-2 neu testing has been done if metastatic disease was present at diagnosis” is a new bullet.

[GAST-C:](#) Principles of Multidisciplinary Team Approach

- Second bullet: Clarified as “**Optimally** at each meeting....” “Palliative care specialist” was added as a supporting discipline.

[GAST-D:](#) Principles of Surgery

- This page was revised to reflect the 7th edition (2010) of the AJCC Staging Manual.

[GAST-E:](#) Principles of Systemic Therapy

- This page was extensively revised (including the addition/deletion of regimens and the addition of dosing schedules).

[GAST-F:](#) Principles of Radiation Therapy

- Simulation and treatment planning: A bullet on Intensity modulated radiation therapy (IMRT) was added.


[GAST-G:](#) Principles of Best Supportive Care

- This page was extensively revised.



NCCN Guidelines™ Version 1.2011

Gastric Cancer



^aSee [Principles of Endoscopic Surgery and Therapy \(GAST-A\)](#).

^bMay not be appropriate for T1 patients.

^cSee [Principles of Pathologic Review and HER2-neu Testing \(GAST-B\)](#).

^dTis or T1a: Defined as carcinoma in situ (Tis) or invasion of mucosa without submucosal invasion (T1a).

^eMedically able to tolerate major abdominal surgery.

^fLaparoscopy is performed to evaluate for peritoneal spread when considering chemoradiation or surgery. Laparoscopy is not indicated if a palliative resection is planned.

^gSee [Principles of Multidisciplinary Team Approach \(GAST-C\)](#).


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines™ Version 1.2011

Gastric Cancer



^a See Principles of Endoscopic Surgery and Therapy (GAST-A).

^d Tis or T1a: Defined as carcinoma in situ (Tis) or invasion of mucosa without submucosal invasion (T1a).

^e Medically able to tolerate major abdominal surgery.

^g See Principles of Multidisciplinary Team Approach (GAST-C).

^h T1b: Tumors invading the submucosa.

ⁱ See Principles of Surgery (GAST-D).


^j Surgery as primary therapy is appropriate for ≥ T1b cancer or actively bleeding cancer, or when postoperative therapy is preferred.

^k See Principles of Systemic Therapy (GAST-E).

^l See Principles of Radiation Therapy (GAST-F).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^kSee Principles of Systemic Therapy (GAST-E).

^lSee Principles of Radiation Therapy (GAST-F).

^mR0= No cancer at resection margins, R1= Microscopic residual cancer, R2= Macroscopic residual cancer or M1B.


ⁿMacdonald JS, Smalley SR, Benedetti J, Hundahl SA, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-730.

^oHigh risk features include poorly differentiated or higher grade cancer, lymphovascular invasion, neural invasion, or < 50 years of age.

^pSee Principles of Best Supportive Care (GAST-G).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^kSee Principles of Systemic Therapy (GAST-E).

^lSee Principles of Radiation Therapy (GAST-F).

^mR0= No cancer at resection margins, R1= Microscopic residual cancer, R2= Macroscopic residual cancer or M1B.

ⁿMacdonald JS, Smalley SR, Benedetti J, Hundahl SA, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-730.

^oHigh risk features include poorly differentiated or higher grade cancer, lymphovascular invasion, neural invasion, or < 50 years of age.

^pSee Principles of Best Supportive Care (GAST-G).

^qSee Staging (ST-1).

^rPostoperative chemoradiation only if not received preoperatively.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



**POST TREATMENT
ASSESSMENT**

OUTCOME

**ADJUNCTIVE
TREATMENT**



ⁱSee Principles of Surgery (GAST-D).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




FOLLOW-UP

PERFORMANCE STATUS

PALLIATIVE THERAPY

- H&P every 3-6 mo for 1-2 y, every 6-12 mo for 3-5 y, then annually
- CBC and chemistry profile as indicated
- Radiologic imaging or endoscopy, as clinically indicated
- Monitor for nutritional deficiency in surgically resected patients and treat as indicated
- Confirm that HER2-neu testing has been done if metastatic disease was present at diagnosis^c



^cSee Principles of Pathologic Review and HER2-neu Testing (GAST-B).

^kSee Principles of Systemic Therapy (GAST-E).

^pSee Principles of Best Supportive Care (GAST-G).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

Endoscopy has become an important tool in the diagnosis, staging, treatment and palliation of patients with gastric cancer. Although some endoscopy procedures can be performed without anesthesia, most are performed with conscious sedation administered by the endoscopist or assisting nurse or deeper anesthesia (monitored anesthesia care) provided by the endoscopist and nurse, a nurse anesthetist, or an anesthesiologist. Some patients who are at risk of aspiration during endoscopy may require general anesthesia.

DIAGNOSIS

- Diagnostic and surveillance endoscopies are performed with the goal of determining the presence and location of neoplastic disease and to biopsy any suspicious lesion. Thus, an adequate endoscopic exam addresses both of these components. The location of the tumor in the stomach (cardia, fundus, body, antrum, and pylorus) and relative to the esophago-gastric junction (EGJ) for proximal tumors should be carefully recorded to assist with treatment planning and follow up examinations.
- Multiple (8-10) biopsies using standard size endoscopy forceps should be performed to provide adequate sized material for histologic interpretation, especially in the setting of an ulcerated lesion.¹ Larger forceps may improve the yield.
- Endoscopic mucosal resection (EMR) of focal nodules ≤ 1.5 cm can be performed in the setting of early stage disease to provide accurate T-staging, with the potential of being therapeutic.² En-bloc excision by endoscopic submucosal dissection (ESD) has been shown to be more effective than EMR in curing early gastric cancer, but requires greater skills and instrumentation to perform and has a significant risk of complications including perforation.³
- Cytologic brushings or washings are rarely adequate in the initial diagnosis, but can be useful in confirming the presence of cancer when biopsies are not diagnostic.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

GAST-A
1 of 3



PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY

STAGING

- Endoscopic ultrasound (EUS) performed prior to any treatment is important in the initial clinical staging of gastric cancer.⁴ Careful attention to ultrasound images, provides evidence of depth of tumor invasion (T-stage), presence of abnormal or enlarged lymph nodes likely to harbor cancer (N-assessment), and occasionally signs of distant spread, such as lesions in surrounding organs (M-stage) or the presence of ascites.⁵ This is especially important in patients who are being considered for EMR.⁶
- Hypoechoic (dark) expansion of the gastric wall layers identifies the location of tumor, with gradual loss of the layered pattern of the normal stomach wall corresponding with greater depths of tumor penetration, correlating with higher T-stages. A dark expansion of layers 1-3 correspond with infiltration of the superficial and deep mucosa plus the submucosal, T1 disease. A dark expansion of layers 1-4, correlates with penetration into the muscularis propria, T2 disease, and expansion beyond the muscularis propria resulting in an irregular outer border correlates with invasion of the subserosa, T3 disease. Loss of the bright line recognized as the serosa is now staged as T4a, and extension of the mass into surrounding organs such as the liver, pancreas, spleen is staged T4b disease.
- Perigastric lymph nodes are readily seen by EUS, and the identification of enlarged, hypoechoic (dark), homogeneous, well circumscribed, rounded structures around the stomach correlates with the presence of malignant or inflammatory lymph nodes. The accuracy of this diagnosis is significantly increased with the combination of features, but also may be confirmed with the use of fine needle aspiration (FNA) biopsy for cytology assessment.⁷ FNA of suspicious lymph nodes should be performed if it can be achieved without traversing an area of primary tumor or major blood vessels, and if it will impact on treatment decisions.

TREATMENT

- EUS exams performed after chemotherapy or radiation therapy have a reduced ability to accurately determine the post-treatment stage of disease.⁸ Similarly, biopsies performed after chemotherapy or radiation therapy may not accurately diagnose the presence of residual disease but still provide useful information.⁹
- Endoscopic tumor ablation can be performed for the short-term control of bleeding. Endoscopic insertion of expandable metal stents is effective in long-term relief of tumor obstruction at the EGJ or the gastric outlet, though surgical gastrojejunostomy may be more efficacious for those with longer-term survival (see [Principles of Best Supportive Care \[GAST-G\]](#)).^{10,11}
- Long-term palliation of anorexia, dysphagia or malnutrition may be achieved with endoscopic or radiographic assisted placement of feeding gastrostomy (PEG) in carefully selected cases where the distal stomach is uninvolved by tumor, or the placement of a feeding jejunostomy (PEJ).¹²

POST-TREATMENT SURVEILLANCE

- Endoscopic surveillance following definitive treatment of gastric cancer requires careful attention to detail for mucosal surface changes, and multiple (4-6) biopsies of any visualized abnormalities. Strictures should be biopsied to rule-out neoplastic cause. EUS performed in conjunction with endoscopy exams has a high sensitivity for recurrent disease.¹³ EUS-guided FNA should be performed if suspicious lymph nodes or areas of wall thickening are seen.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF ENDOSCOPIC STAGING AND THERAPY
(REFERENCES)

- ¹Hatfield AR, Slavin G, Segal AW, Levi AJ. Importance of the site of endoscopic gastric biopsy in ulcerating lesions of the stomach. *Gut*. 1975;16:884-886.
- ²Akiyama M, Ota M, Nakajima H, Yamagata K, Munakata A. Endoscopic mucosal resection of gastric neoplasms using a ligating device. *Gastrointest Endosc*. 1997;45:182-186.
- ³Yahagi N, Fujishiro M, Kakushima N, et al. Endoscopic submucosal dissection for early gastric cancer using the tip of an electrosurgical snare (thin type). *Digestive Endoscopy*. 2004;16:34-38.
- ⁴Botet JF, Lightdale CJ, Zauber AG, et al. Endoscopic ultrasound in the pre-operative staging of gastric cancer: A comparative study with dynamic CT. *Radiology*. 1991; 181: 426-432.
- ⁵Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. *Ann Surg Oncol*. 2007;14:1853-1859.
- ⁶Okada K, Fujisaki J, Kasuga A, et al., Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. *Surg Endosc*. 2010, 1279-1284.
- ⁷Keswani RN, Early DS, Edmundowicz SA, et al. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. *Gastrointest Endosc* 2009;69:1210-7.
- ⁸Park SR, Lee JS, Kim CG, et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. *Cancer* 2008;112:2368-2376.
- ⁹Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment Endoscopic Biopsy Is a Poor-Predictor of Pathologic Response in Patients Undergoing Chemoradiation Therapy for Esophageal Cancer. *Ann Surg* 2009;249:764–767.
- ¹⁰Schmidt C, Gerdes H, Hawkins W, et al. A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction. *Am J Surg*. 2009;198:92-99.
- ¹¹Vakil N, Morris AI, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. *Am J Gastroenterol*. 2001;96:1791-1796.
- ¹²Shike M, Latkany L, Gerdes H, Bloch AS. Direct percutaneous endoscopic jejunostomies for enteral feeding. *Gastrointest Endosc*. 1996;44:536-540.
- ¹³Lightdale CJ, Botet JF, Kelsen DP, Turnbull AD, Brennan MF. Diagnosis of recurrent upper gastrointestinal cancer at the surgical anastomosis by endoscopic ultrasound. *Gastrointest Endosc*. 1989;35:407-412.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF PATHOLOGIC REVIEW AND HER2-NEU TESTING****TABLE 1**

Specimen Type	Analysis/Interpretation/Reporting^a
Endoscopic mucosal resection	Include in pathology report: <ul style="list-style-type: none"> • Invasion, if present • Histologic type^b • Grade • Depth of tumor invasion • Vascular invasion • Status of mucosal and deep margins
Gastrectomy, without prior chemoradiation	For pathology report, include all elements as for endoscopic mucosal resection plus <ul style="list-style-type: none"> • Location of tumor midpoint in relationship to EGJ^c • Whether tumor crosses EGJ • LN status and number of lymph nodes recovered
Gastrectomy, with prior chemoradiation	<p>Tumor site should be thoroughly sampled for specimens s/p neoadjuvant therapy without grossly obvious residual tumor</p> <p>For pathology report, include all elements as for resection without prior chemo/radiation plus assessment of treatment effect</p>

^aUse of a standardized minimum data set such as the College of American Pathologists Cancer Protocols (available at <http://www.cap.org>) for reporting pathologic findings is recommended.

^bSubclassification of gastric adenocarcinomas as intestinal or diffuse type may have implications for therapy, as intestinal type cancers may be more likely to overexpress HER2-neu.¹

^cTumors arising in the proximal stomach and crossing the EGJ are classified for purposes of staging as esophageal carcinomas.²

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued

**PRINCIPLES OF PATHOLOGIC REVIEW AND HER2-NEU TESTING****Assessment of treatment response**

Response of the primary tumor to previous chemotherapy or radiation therapy should be reported. Although grading systems for tumor response in gastric cancer have not been uniformly adopted, in general, three-category systems provide good reproducibility among pathologists. The following system developed for rectal carcinoma is reported to provide good interobserver agreement, but other systems may also be used. Sizable pools of acellular mucin may be present after chemoradiation but should not be interpreted as representing residual tumor.

TABLE 2

Tumor Regression Grade	Description
0 (Complete response)	No cancer cells
1 (Moderate response)	Single cells or small groups of cancer cells
2 (Minimal response)	Residual cancer outgrown by fibrosis
3 (Poor response)	Minimum or no treatment effect; extensive residual cancer cells

Number of lymph nodes retrieved

- While there is no universally accepted minimum number of lymph nodes necessary for accurate staging of gastric cancer, retrieval of at least 15 lymph nodes is recommended to avoid stage migration.^{4,5}

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued

**PRINCIPLES OF PATHOLOGIC REVIEW AND HER2-NEU TESTING****Assessment of Overexpression of HER2-neu in Gastric Carcinoma**

For patients with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or esophagogastric junction for whom trastuzumab therapy is being considered, assessment for tumor HER2-neu overexpression should be performed using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).⁶ The following criteria used in the ToGA trial⁶ are recommended:

TABLE 3: Immunohistochemical Criteria for Scoring HER2-neu Expression in Gastric and Esophagogastric Carcinoma

	Surgical Specimen Expression Pattern, Immunohistochemistry	Biopsy Specimen Expression Pattern, Immunohistochemistry	HER2-neu Overexpression Assessment
0	No reactivity or membranous reactivity in < 10% of cancer cells	No reactivity or no membranous reactivity in any cancer cell	Negative
1+	Faint or barely perceptible membranous reactivity in ≥ 10% of cancer cells; cells are reactive only in part of their membrane	Cancer cell cluster with a faint or barely perceptible membranous reactivity irrespective of percentage of cancer cells positive	Negative
2+	Weak to moderate complete, basolateral or lateral membranous reactivity in > 10% of tumor cells	Cancer cell cluster with a weak to moderate complete, basolateral, or lateral membranous reactivity irrespective of percentage of cancer cells positive	Equivocal (FISH testing is recommended)
3+	Strong complete, basolateral or lateral membranous reactivity in ≥ 10% of cancer cells	Cancer cell cluster with a strong complete, basolateral, or lateral membranous reactivity irrespective of percentage of cancer cells positive	Positive

Cases showing 2+ (equivocal) overexpression of HER2-neu by immunohistochemistry should be additionally examined by FISH or other in situ hybridization methods.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF PATHOLOGIC REVIEW AND HER2-NEU TESTING

- ¹Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. *Histopathology*. 2008;52:797-805.
- ²Edge SE, Byrd DR, Carducci MA, Compton CC. *AJCC TNM Staging Manual*. 7th ed. New York, NY: Springer 2009.
- ³Ryan R, Gibbons D, Hyland JMP, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology*. 2005;47:141-146.
- ⁴Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. *Cancer*. 2000 Feb 15;88(4):921-932.
- ⁵Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. *Journal of Clinical Oncology*. 2005 Oct 1;23(28):7114-7124.
- ⁶Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*. 2010;376(9742):687-697.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF MULTIDISCIPLINARY TEAM APPROACH FOR ESOPHAGOGASTRIC CANCERS

Category 1 evidence supports the notion that the combined modality therapy is effective for patients with localized esophagogastric cancer.^{1,2,3} The NCCN panel believes in an infrastructure that encourages multidisciplinary treatment decision-making by members of all disciplines taking care of this group of patients.

The combined modality therapy for patients with localized esophagogastric cancer may be optimally delivered when the following elements are in place:

- **The involved institution and individuals from relevant disciplines are committed to jointly reviewing the detailed data on patients on a regular basis. Frequent meetings (either once a week or once every two weeks) are encouraged.**
- **Optimally at each meeting, all relevant disciplines should be encouraged to participate and these may include: surgical oncology, medical oncology, gastroenterology, radiation oncology, radiology, and pathology. In addition, the presence of nutritional services, social workers, nursing, palliative care specialists, and other supporting disciplines are also desirable.**
- **All long-term therapeutic strategies are best developed after adequate staging procedures are completed, but ideally prior to any therapy that is rendered.**
- **Joint review of the actual medical data is more effective than reading reports for making sound therapy decisions.**
- **A brief documentation of the consensus recommendation(s) by the multidisciplinary team for an individual patient may prove useful.**
- **The recommendations made by the multidisciplinary team may be considered advisory to the primary group of treating physicians of the particular patient.**
- **Re-presentation of select patient outcomes after therapy is rendered may be an effective educational method for the entire multidisciplinary team.**
- **A periodic formal review of relevant literature during the course of the multidisciplinary meeting is highly encouraged.**

¹Cunningham D, Allum WH, Stenning SP, Thompson JN, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355(1):11-20.

²Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr., Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). *Radiation Therapy Oncology Group. JAMA* 1999;281(17):1623-1627.

³Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345(10):725-730.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF SURGERY

Staging

- Determine extent of disease with CT scan ± EUS
- Laparoscopy¹ may be useful in select patients in detecting radiographically occult metastatic disease
- Positive peritoneal cytology (performed in the absence of visible peritoneal implants), is associated with poor prognosis and should be considered as M1 disease. Patients with advanced tumors, clinical T3 or N+ disease should be considered for laparoscopic staging with peritoneal washings.²

Criteria of unresectability for cure

- Locoregionally advanced
 - Level 3 or 4 lymph node highly suspicious on imaging or confirmed by biopsy
 - Invasion or encasement of major vascular structures
- Distant metastasis or peritoneal seeding (including positive peritoneal cytology)

Resectable tumors

- Tis or T1³ tumors limited to mucosa (T1a) may be candidates for endoscopic mucosal resection (in experienced centers)⁴
- T1b-T3⁵: Adequate gastric resection to achieve negative microscopic margins (typically ≥ 4 cm from gross tumor).
 - Distal gastrectomy
 - Subtotal gastrectomy
 - Total gastrectomy
- T4 tumors require en bloc resection of involved structures
- Gastric resection should include the regional lymphatics-- perigastric lymph nodes (D1) and those along the named vessels of the celiac axis (D2), with a goal of examining at least 15 or greater lymph nodes^{6,7,8}
- Routine or prophylactic splenectomy is not required.⁹ Splenectomy is acceptable when the spleen or the hilum is involved.
- Consider placing feeding jejunostomy tube in select patients (especially if postoperative chemoradiation appears a likely recommendation)

Unresectable tumors (palliative procedures)

- Palliative gastric resection should not be performed unless patient is symptomatic.
- Lymph node dissection not required
- Gastric bypass with gastrojejunostomy to the proximal stomach instead of self-expanding metal stenting in symptomatic patients if they are fit for surgery and have a reasonable prognosis due to the lower rate of recurrent symptoms¹⁰
- Venting gastrostomy and/or jejunostomy tube may be considered

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

PRINCIPLES OF SURGERY

- ¹Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. *Am J Surg.* 2006;191(1):134-138.
- ²Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients. *Ann Surg Oncol.* 2010 Jun 29. [Epub ahead of print] PMID: 20585870.
- ³Soetikno R, Kaltenbac T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol.* 2005;23(20):4490-4498.
- ⁴Ono H, Kondo H, Gotoda T, Shirao K, et al. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001; 48: 225-229.
- ⁵Ito H, Clancy TE, Osteen RT, Swanson RS, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? *J Am Coll Surg.* 2004;199(6):880-886.
- ⁶Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol.* 2004;22(11):2069-2077.
- ⁷Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol.* 2007;14(2):317-328.
- ⁸Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. *Ann Surg.* 2000 Sep;232(3):362-571.
- ⁹Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg.* 2006;93(5):559-563.
- ¹⁰Jeurnink SM, van Eijck CH, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol* 2007;7:18-27.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF SYSTEMIC THERAPY

- **Chemotherapy regimens recommended for advanced esophageal/esophagogastric adenocarcinoma, squamous cell carcinoma of the esophagus, and gastric adenocarcinoma may be used interchangeably (except as indicated).**
- **Regimens should be chosen in the context of performance status, medical comorbidities, toxicity profile, and HER2-neu expression (for adenocarcinoma only).**
- **The use of three-drug regimens for advanced disease should be reserved for patients who are medically fit, with a good performance status (ECOG performance status of 0 or 1), and with access to frequent toxicity assessment.**
- **Modifications of category 1 regimens or use of category 2A or 2B regimens may be preferred (as indicated), with evidence supporting more favorable toxicity profile without a compromise of efficacy.**
- **Doses and schedules for any regimen that is not derived from category 1 evidence is a suggestion, and subject to appropriate modifications depending on the circumstances.**
- **Alternate combinations and schedules of cytotoxics based on the availability of the agents, practice preferences, and contraindications are permitted.**
- **Infusional 5-FU and capecitabine may be used interchangeably (except as indicated). Infusion is the preferred route compared with bolus 5-FU.¹**
- **Cisplatin and oxaliplatin may be used interchangeably depending on toxicity profile.**
- **For localized esophagogastric/gastric cardia adenocarcinoma, preoperative chemoradiation is the preferred approach.**
- **For localized stomach cancer, perioperative chemotherapy² or postoperative chemotherapy plus chemoradiation³ is the preferred approach.**
- **Upon completion of chemotherapy, patients should be assessed for response and monitored for any long-term complications.**
- **Please refer to the Principles of Radiation Therapy for the radiation therapy administration details. ([GAST-F](#))**

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF SYSTEMIC THERAPY

Preoperative Chemoradiation (EG junction and gastric cardia):

- Paclitaxel and carboplatin (category 1)^{4,5}
- Cisplatin and fluoropyrimidine (5-FU or capecitabine) (category 1)⁶⁻⁹
- Oxaliplatin and fluoropyrimidine (5-FU[†] or capecitabine)¹⁰⁻¹³
- Paclitaxel or docetaxel and cisplatin¹⁴⁻¹⁶
- Carboplatin and 5-FU (category 2B)¹⁷
- Irinotecan and cisplatin (category 2B)^{14,18-20}
- Docetaxel or paclitaxel and fluoropyrimidine (5-FU or capecitabine) (category 2B)²¹⁻²⁵
- Oxaliplatin, docetaxel, and capecitabine (category 2B)²⁵

Perioperative Chemotherapy (including EG junction)

(3 cycles preoperative and 3 cycles postoperative):

- ECF (epirubicin, cisplatin and 5-FU) (category 1)²
- ECF modifications (category 1)²⁶

Postoperative Chemoradiation (including EG junction):

- 5-FU (bolus) and leucovorin (category 1)³
- LV5FU2 before and after infusion 5-FU or capecitabine with radiation (preferred)²⁷⁻²⁹
- Paclitaxel and 5-FU (category 2B)²¹

[†]Leucovorin is indicated with certain 5-FU-based regimens.

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY****Definitive Chemotherapy for Metastatic or Locally Advanced Cancer [where chemoradiation is not indicated]****First Line Therapy**

Two-drug regimens or single agent preferred. Three-drug regimens should be reserved for medically fit patients with good PS and access to frequent toxicity evaluation.

- Trastuzumab with chemotherapy for HER2-neu overexpressing adenocarcinoma (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines)³⁰

[\[See Principles of Pathologic Review and HER2-neu Testing \(GAST-B\)\]](#)

- DCF (docetaxel, cisplatin and 5-FU[†]) (category 1)³¹
- DCF modifications (preferred over DCF) (category 2A; category 2B for docetaxel, carboplatin, and 5-FU)³²⁻³⁶
- ECF (category 1)^{37,38}
- ECF modifications (category 1)³⁸
- Fluoropyrimidine (5-FU[†] or capecitabine) and cisplatin (category 1)^{30,39-41}
- Fluoropyrimidine (5-FU[†] or capecitabine) and oxaliplatin^{39,42}
- 5-FU[†] and irinotecan^{40,43-45}
- Paclitaxel with cisplatin or carboplatin⁴⁶⁻⁴⁸
- Docetaxel with cisplatin^{35,49,50}
- Docetaxel and irinotecan (category 2B)⁵¹
- Fluoropyrimidine (5-FU[†] or capecitabine)^{40,52,53}
- Docetaxel or paclitaxel⁵⁴⁻⁵⁶

[†]Leucovorin is indicated with certain 5-FU-based regimens.

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Second-Line Therapy

Dependent on prior therapy and performance status (PS):

- Trastuzumab with chemotherapy for HER2-neu overexpressing adenocarcinoma if not used in first line therapy (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines)³⁰

[\[See Principles of Pathologic Review and HER2-neu Testing \(GAST-B\)\]](#)

- Irinotecan and cisplatin^{42,57}
- Irinotecan and fluoropyrimidine (5-FU[†] or capecitabine) (category 2B)^{58,59}
- Irinotecan and docetaxel⁵¹
- Irinotecan and mitomycin (category 2B)^{60,61}
- Docetaxel or paclitaxel (category 2B)⁵⁴⁻⁵⁶
- Irinotecan (category 2B)⁶²⁻⁶⁴

Alternative regimens to be considered (these may be combined with other agents when appropriate) (category 2B):

- Gemcitabine, 5-FU and leucovorin⁶⁵
- Pegylated liposomal doxorubicin, cisplatin and 5-FU⁶⁶
- Mitomycin and irinotecan⁶⁷
- Mitomycin, cisplatin, and 5-FU³⁷
- Mitomycin and 5-FU[†]⁶⁸
- Etoposide⁶⁹⁻⁷⁰
- Erlotinib^{71,72}
- Cetuximab⁷³

[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY--REGIMENS AND DOSING SCHEDULES****PREOPERATIVE CHEMORADIATION (EG JUNCTION AND GASTRIC CARDIA)****Paclitaxel and carboplatin**

Paclitaxel 50 mg/m² IV on Day 1
Carboplatin AUC 2 IV on Day 1
Weekly for 5 weeks^{4,5}

Cisplatin and fluoropyrimidine

Cisplatin 75-100 mg/m² IV on Day 1
5-FU 750-1000 mg/m² IV continuous infusion
over 24 hours daily on Days 1-4
Cycled every 28 days for 2-4 cycles^{6,7}

Cisplatin 30 mg/m² IV on Day 1
Capecitabine 800 mg/m² PO BID on Days 1-5
Weekly for 5 weeks⁸

Cisplatin 15 mg/m² IV daily on Days 1-5
5-FU 800 mg/m² IV continuous infusion
over 24 hours daily on Days 1-5
Cycled every 21 days for 2 cycles⁹

Oxaliplatin and fluoropyrimidine

Oxaliplatin 45-50 mg/m² IV on Day 1 weekly for 5 weeks
5-FU 225 mg/m² IV daily on Days 1-4¹⁰

Oxaliplatin 85 mg/m² IV on Days 1, 15, and 29 for 3 doses
5-FU 180 mg/m² IV daily on Days 1-4¹¹

Oxaliplatin 85 mg/m² IV on Days 1, 15, and 29 for 3 doses
Capecitabine 625-825 mg/m² PO BID
on Days 1-5 for 5 weeks¹²

Oxaliplatin 85 mg/m² IV on Day 1
Leucovorin 400 mg/m² IV on Day 1
5-FU 400 mg/m² IVP on Day 1
5-FU 1200 mg/m² IV continuous infusion
over 24 hours daily on Days 1 and 2
Cycled every 14 days for 3 cycles¹³

Taxane and cisplatin

Paclitaxel 50 mg/m² IV on Day 1
Cisplatin 25-30 mg/m² IV on Day 1
Weekly for 5 weeks¹⁴

Docetaxel 20 mg/m² IV
on Days 1, 8, 15, 22, and 29
Cisplatin 25-30 mg/m² IV
on Day 1, 8, 15, 22, and 29
Given for 1 cycle¹⁵

Paclitaxel 60 mg/m² IV
on Days 1, 8, 15, and 22
Cisplatin 75 mg/m² IV
on Day 1, 8, 15, 22, and 29
Given for 1 cycle¹⁶

Carboplatin and 5-FU

Carboplatin AUC 6 IV on Days 1 and 22
5-FU 200 mg/m² IV daily on Days 1-4¹⁷

Irinotecan and cisplatin

Irinotecan 50-65 mg/m² IV
on Days 1, 8, (15,) 22, (29)
Cisplatin 25-30 mg/m² IV
on Days 1, 8, (15,) 22, (29)^{14,18-20}

Taxane and fluoropyrimidine

Paclitaxel 45-50 mg/m² IV on Day 1
5-FU 200-300 mg/m² IV daily on Days 1-5
Weekly for 5 weeks^{21,22}

Paclitaxel 45-50 mg/m² IV on Day 1
Capecitabine 625-825 mg/m² PO BID
on Days 1-5
Weekly for 5 weeks^{21,23}

Docetaxel 20 mg/m² IV on Day 1
5-FU 200-300 mg/m² IV daily on Days 1-5
Weekly for 5 weeks^{24,25}

Docetaxel 20 mg/m² IV on Day 1
Capecitabine 625-825 mg/m² PO BID
on Days 1-5
Weekly for 5 weeks^{23,25}

Oxaliplatin, docetaxel, and capecitabine

Oxaliplatin 40 mg/m² IV
on Days 1, 8, 15, 22, and 29
Docetaxel 20 mg/m² IV
on Days 1, 8, 15, 22, and 29
Capecitabine 1000 mg/m² PO BID
on Days 1-7, 15-21, and 29-35
Given for 1 cycle²⁵

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY--REGIMENS AND DOSING SCHEDULES****PERIOPERATIVE CHEMOTHERAPY (INCLUDING EG JUNCTION)****ECF (epirubicin, cisplatin, and 5-FU)**Epirubicin 50 mg/m² IV on Day 1Cisplatin 60 mg/m² IV on Day 15-FU 200 mg/m² IV continuous infusion over 24 hours daily on Days 1-21

Cycled every 21 days for 3 cycles preoperatively

and 3 cycles postoperatively²**ECF modifications**Epirubicin 50 mg/m² IV on Day 1Oxaliplatin 130 mg/m² IV on Day 15-FU 200 mg/m² IV continuous infusion over 24 hours daily on Days 1-21

Cycled every 21 days for 3 cycles preoperatively

and 3 cycles postoperatively²⁶Epirubicin 50 mg/m² IV on Day 1Cisplatin 60 mg/m² IV on Day 1Capecitabine 625 mg/m² PO BID on Days 1-21

Cycled every 21 days for 3 cycles preoperatively

and 3 cycles postoperatively²⁶Epirubicin 50 mg/m² IV on Day 1Oxaliplatin 130 mg/m² IV on Day 1Capecitabine 625 mg/m² PO BID on Days 1-21

Cycled every 21 days for 3 cycles preoperatively

and 3 cycles postoperatively²⁶

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTOPERATIVE CHEMORADIATION (INCLUDING EG JUNCTION)**5-FU (bolus) and leucovorin**

Cycles 1, 4, and 5 (before and after radiation)

Leucovorin 20 mg/m² IVP on Days 1-55-FU 425 mg/m² IVP daily on Days 1-5Cycled every 28 days³

Cycles 2 and 3 (with radiation)

Leucovorin 20 mg/m² IVP on Days 1-3 (4)5-FU 400 mg/m² IVP daily on Days 1-3 (4)Cycled every 28 days³**LV5FU2 before and after infusional 5-FU or capecitabine (preferred)**

1 cycle before and 2 cycles after radiation

Leucovorin 400 mg/m² IV on Days 1 and 25-FU 400 mg/m² IVP on Days 1 and 25-FU 1200 mg/m² IV continuous infusion

over 24 hours daily on Days 1 and 2

Every 14 days for 2 doses/cycle²⁷

With radiation

5-FU 200-250 mg/m² IV continuous infusion

over 24 hours daily on Days 1-5 or 1-7

Weekly for 5 weeks²⁸

With radiation

Capecitabine 625-825 mg/m² PO BID on Days 1-5 or 1-7Weekly for 5 weeks²⁹**Paclitaxel and 5-FU**Paclitaxel 45-50 mg/m² IV on Day 15-FU 300 mg/m² IV continuous infusion

over 24 hours daily on Days 1-5

Weekly for 5 weeks²¹[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY--REGIMENS AND DOSING SCHEDULES****DEFINITIVE CHEMOTHERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE CHEMORADIATION IS NOT INDICATED)****FIRST-LINE THERAPY****Trastuzumab (with chemotherapy)**

Trastuzumab 8 mg/kg IV loading dose on Day 1 of Cycle 1, then Trastuzumab 6 mg/kg IV every 21 days³⁰

DCF (docetaxel, cisplatin, and 5-FU)

Docetaxel 75 mg/m² IV on Day 1
Cisplatin 75 mg/m² IV on Day 1
5-FU 1000 mg/m² IV continuous infusion over 24 hours daily on Days 1-5
Cycled every 28 days³¹

DCF modifications

Docetaxel 40 mg/m² IV on Day 1
Leucovorin 400 mg/m² IV on Day 1
5-FU 400 mg/m² IV on Day 1
5-FU 1000 mg/m² IV continuous infusion over 24 hours daily on Days 1 and 2
Cisplatin 40 mg/m² IV on Day 3
Cycled every 14 days³²

Docetaxel 50 mg/m² IV on Day 1
Oxaliplatin 85 mg/m² IV on Day 1
Leucovorin 200 mg/m² IV on Day 1
5-FU 2600 mg/m² IV continuous infusion over 24 hours daily on Day 1
Cycled every 14 days³³

DCF modifications---continued

Docetaxel 50 mg/m² IV on Day 1
Oxaliplatin 85 mg/m² IV on Day 1
5-FU 1200 mg/m² IV continuous infusion over 24 hours daily on Days 1 and 2
Cycled every 14 days³³

Docetaxel 60 mg/m² IV on Day 1
Cisplatin 60 mg/m² IV on Day 1
5-FU 750 mg/m² IV continuous infusion over 24 hours daily on Days 1-4
Cycled every 21 days³⁴

Docetaxel 85 mg/m² IV on Day 1
Cisplatin 75 mg/m² IV on Day 1
5-FU 300 mg/m² IV continuous infusion over 24 hours daily on Days 1-14
Cycled every 21 days³⁵

Docetaxel 75 mg/m² IV on Day 1
Carboplatin AUC 6 IV on Day 2
5-FU 1200 mg/m² IV continuous infusion over 24 hours daily on Days 1-3
Cycled every 21 days³⁶

ECF

Epirubicin 50 mg/m² IV on Day 1
Cisplatin 60 mg/m² IV on Day 1
5-FU 200 mg/m² IV continuous infusion over 24 hours daily on Days 1-21
Cycled every 21 days^{37,38}

ECF modifications

Epirubicin 50 mg/m² IV on Day 1
Oxaliplatin 130 mg/m² IV on Day 1
5-FU 200 mg/m² IV continuous infusion over 24 hours daily on Days 1-21
Cycled every 21 days³⁸

Epirubicin 50 mg/m² IV on Day 1
Cisplatin 60 mg/m² IV on Day 1
Capecitabine 625 mg/m² PO BID on Days 1-21
Cycled every 21 days³⁸

Epirubicin 50 mg/m² IV on Day 1
Oxaliplatin 130 mg/m² IV on Day 1
Capecitabine 625 mg/m² PO BID on Days 1-21
Cycled every 21 days³⁸

Fluoropyrimidine and cisplatin

Cisplatin 75-100 mg/m² IV on Day 1
5-FU 750-1000 mg/m² IV continuous infusion over 24 hours daily on Days 1-4
Cycled every 21-28 days for 2-4 cycles³⁰

Cisplatin 50 mg/m² IV daily on Day 1
Leucovorin 200 mg/m² IV on Day 1
5-FU 2000 mg/m² IV continuous infusion over 24 hours daily on Day 1
Cycled every 14 days^{39,40}

Cisplatin 80 mg/m² IV daily on Day 1
Capecitabine 1000 mg/m² PO BID on Days 1-14
Cycled every 21 days^{30,41}

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY--REGIMENS AND DOSING SCHEDULES****DEFINITIVE CHEMOTHERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE CHEMORADIATION IS NOT INDICATED)****FIRST-LINE THERAPY---continued****Fluoropyrimidine and oxaliplatin**

Oxaliplatin 85 mg/m² IV on Day 1
Leucovorin 400 mg/m² IV on Day 1
5-FU 400 mg/m² IVP on Day 1
5-FU 1200 mg/m² IV continuous infusion
over 24 hours daily on Days 1 and 2
Cycled every 14 days⁴²

Oxaliplatin 85 mg/m² IV on Day 1
Leucovorin 200 mg/m² IV on Day 1
5-FU 2600 mg/m² IV continuous infusion over 24 hours on Day 1
Cycled every 14 days³⁹

5-FU and irinotecan

Irinotecan 80 mg/m² IV on Day 1
Leucovorin 500 mg/m² IV on Day 1
5-FU 2000 mg/m² IV continuous infusion over 24 hours on Day 1
Weekly for 6 weeks followed by 1 week off treatment⁴³

Irinotecan 180 mg/m² IV on Day 1
Leucovorin 400 mg/m² IV on Day 1
5-FU 400 mg/m² IVP on Day 1
5-FU 1200 mg/m² IV continuous infusion
over 24 hours daily on Days 1 and 2
Cycled every 14 days^{40,44}

Irinotecan 80 mg/m² IV on Day 1
Leucovorin 500 mg/m² IV combined with
5-FU 2000 mg/m² IV continuous infusion over 24 hours on Day 1
Weekly for 6 weeks followed by 2 weeks off treatment⁴⁵

Paclitaxel with cisplatin or carboplatin

Paclitaxel 135 mg/m² IV on Day 1
Cisplatin 75 mg/m² IV on Day 2
Cycled every 21 days⁴⁶

Paclitaxel 90 mg/m² IV on Day 1
Cisplatin 50 mg/m² IV on Day 1
Cycled every 14 days⁴⁷

Paclitaxel 200 mg/m² IV on Day 1
Carboplatin AUC 6 IV on Day 1
Cycled every 21 days⁴⁸

Docetaxel and cisplatin

Docetaxel 70-85 mg/m² IV on Day 1
Cisplatin 70-75 mg/m² IV on Day 1
Cycled every 21 days^{35,49,50}

Docetaxel and irinotecan

Docetaxel 35 mg/m² IV on Days 1 and 8
Irinotecan 50 mg/m² IV on Days 1 and 8
Cycled every 21 days⁵¹

Fluoropyrimidine

Leucovorin 400 mg/m² IV on Day 1
5-FU 400 mg/m² IVP on Day 1
5-FU 1200 mg/m² IV continuous infusion
over 24 hours daily on Days 1 and 2
Cycled every 14 days⁴⁰

5-FU 800 mg/m² IV continuous infusion
over 24 hours daily on Days 1-5
Cycled every 28 days⁵²

Capecitabine 1000 mg/m² PO BID
on Days 1-14
Cycled every 21 days⁵³

Taxane

Docetaxel 75-100 mg/m² IV on Day 1
Cycled every 21 days⁵⁴

Paclitaxel 135-175 mg/m² IV on Day 1
Cycled every 21 days⁵⁵

Paclitaxel 80 mg/m² IV on Day 1 weekly
Cycled every 28 days⁵⁶

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY--REGIMENS AND DOSING SCHEDULES****DEFINITIVE CHEMOTHERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE CHEMORADIATION IS NOT INDICATED)**
SECOND-LINE THERAPY**Trastuzumab (with chemotherapy)**

Trastuzumab 8 mg/kg IV loading dose
on Day 1 of Cycle 1, then
Trastuzumab 6 mg/kg IV every 21 days³⁰

Irinotecan and cisplatin

Irinotecan 65 mg/m² IV on Days 1 and 8
Cisplatin 25-30 mg/m² IV on Days 1 and 8
Cycled every 21 days^{42,57}

Irinotecan and fluoropyrimidine

Irinotecan 250 mg/m² IV on Day 1
Capecitabine 1000 mg/m² PO BID
on Days 1-14
Cycled every 21 days⁵⁸

Irinotecan 180 mg/m² IV on Day 1
Leucovorin 400 mg/m² IV on Day 1
5-FU 400 mg/m² IVP on Day 1
5-FU 1200 mg/m² IV continuous infusion
over 24 hours daily on Days 1 and 2
Cycled every 14 days⁵⁹

Irinotecan and docetaxel

Docetaxel 35 mg/m² IV on Days 1 and 8
Irinotecan 50 mg/m² IV on Days 1 and 8
Cycled every 21 days⁵¹

Irinotecan and mitomycin

Irinotecan 150 mg/m² IV on Days 1 and 8
Mitomycin 8 mg/m² IV on Day 1
Cycled every 28 days⁶⁰

Irinotecan 125 mg/m² Day 1
Mitomycin 5 mg/m² IV on Day 1
Cycled every 14 days⁶¹

Taxane

Docetaxel 75-100 mg/m² IV on Day 1
Cycled every 21 days⁵⁴

Paclitaxel 135-175 mg/m² IV on Day 1
Cycled every 21 days⁵⁵

Paclitaxel 80 mg/m² IV on Day 1 weekly
Cycled every 28 days⁵⁶

Irinotecan

Irinotecan 250-350 mg/m² IV on Day 1
Cycled every 21 days⁶²

Irinotecan 180 mg/m² IV on Day 1
Cycled every 14 days^{63,64}

Irinotecan 125 mg/m² IV on Days 1 and 8
Cycled every 21 days^{63,64}

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF SYSTEMIC THERAPY--REGIMENS AND DOSING SCHEDULES

DEFINITIVE CHEMOTHERAPY FOR METASTATIC OR LOCALLY ADVANCED CANCER (WHERE CHEMORADIATION IS NOT INDICATED)

ALTERNATIVE REGIMENS FOR CONSIDERATION

Gemcitabine, 5-FU, and leucovorin

Gemcitabine 1000 mg/m² IV on Days 1, 8, and 15
Leucovorin 20 mg/m² IV on Days 1, 8, and 15
5-FU 500 mg/m² IV on Days 1, 8, and 15
Cycled every 28 days⁶⁵

Pegylated liposomal doxorubicin, cisplatin, and 5-FU

Pegylated liposomal doxorubicin 20 mg/m² IV on Day 1
Cisplatin 50 mg/m² IV on Day 1
5-FU 400 mg/m² IVP on Day 1
5-FU 600 mg/m² IV continuous infusion over 24 hours daily on Days 1 and 2
Cycled every 14 days⁶⁶

Mitomycin and irinotecan

Mitomycin 6 mg/m² IV on Day 1
Irinotecan 125 mg/m² IV on Days 2 and 9
Cycled every 28 days⁶⁷

Mitomycin, cisplatin, and 5-FU

Mitomycin 7 mg/m² (maximum 14 mg) IV on Day 1
Cisplatin 60 mg/m² IV on Days 1 and 22
5-FU 300 mg/m² IV on Days 1-42
Cycled every 6 weeks³⁷

Mitomycin, leucovorin, and 5-FU

Mitomycin 10 mg/m² IV on Days 1 and 22
Leucovorin 500 mg/m² IV on Day 1
5-FU 2600 mg/m² IV continuous infusion over 24 hours on Day 1
Weekly for 6 weeks followed by 2 weeks off treatment⁶⁸

Etoposide

Etoposide 90-120 mg/m² IV on Days 1-3
Cycled every 28 days^{69,70}

Erlotinib

Erlotinib 150 mg PO daily^{71,72}

Cetuximab (single agent or with chemotherapy)

Cetuximab 400 mg/m² IV Day 1 of Week 1, then
Cetuximab 250 mg/m² IV Day 1 weekly beginning with Week 2⁷³

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, nutritional status, and comorbidity. The optimal delivery of anticancer agents therefore requires a health care delivery team experienced in the use of anticancer agents and the management of associated toxicities in patients with cancer.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

PRINCIPLES OF SYSTEMIC THERAPY--REFERENCES

¹Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. *Journal of Clinical Oncology* 2006;24:2903-2909.

²Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20.

³Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730.

⁴van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with esophageal cancer: a phase II study. *Br J Cancer* 2006;94:1389-1394.

⁵Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. *J Clin Oncol (Meeting Abstracts)* 2010;28:4004-.

⁶Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 1992;326:1593-1598.

⁷Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086-1092.

⁸Lee SS, Kim SB, Park SI, et al. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. *Jpn J Clin Oncol* 2007;37:829-835.

⁹Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 2007;25:1160-1168.

¹⁰Lorenzen S, Brucher B, Zimmermann F, et al. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. *Br J Cancer* 2008;99:1020-1026.

¹¹Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. *J Clin Oncol* 2002;20:2844-2850.

¹²Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200.

¹³Conroy T, Viret F, Francois E, et al. Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. *Br J Cancer* 2008;99:1395-1401.

¹⁴Kleinberg L, Powell ME, Forastiere AA, et al. Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. *J Clin Oncol (Meeting Abstracts)* 2008;26:4532-.

¹⁵Ruhstaller T, Widmer L, Schuller JC, et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). *Ann Oncol* 2009;20:1522-1528.

¹⁶Urba SG, Orringer MB, Iannettoni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. *Cancer* 2003;98:2177-2183.

¹⁷Zemanova M, Petruzalka L, Pazdro A, et al. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. *Dis Esophagus* 2010;23:160-167.

¹⁸Sharma R, Yang GY, Nava HR, et al. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). *J Clin Oncol (Meeting Abstracts)* 2009;27:e15619-.

¹⁹Rivera F, Galan M, Taberero J, et al. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2009;75:1430-1436.

²⁰Ku GY, Bains M, Rizk N, et al. Phase II trial of preoperative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure [abstract] [abstract]. Presented at the Gastrointestinal Cancers Symposium Abstract 9.

²¹Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958.

²²Schnirer, II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. *Am J Clin Oncol* 2001;24:91-95.

²³Czito BG, Kelsey CR, Hurwitz HI, et al. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2007;67:1002-1007.

²⁴Hihara J, Yoshida K, Hamai Y, et al. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. *Anticancer Res* 2007;27:2597-2603.

²⁵Spigel DR, Greco FA, Meluch AA, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 2010;28:2213-2219.

²⁶Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. *Br J Cancer* 2005;92:1976-1983.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**PRINCIPLES OF SYSTEMIC THERAPY--REFERENCES**

²⁷Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. *J Clin Oncol* 2007;25:3732-3738.

²⁸Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-Fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-Fluorouracil: a multicenter study of the trans-tasman radiation oncology group. *Int J Radiat Oncol Biol Phys* 2011;79:690-695.

²⁹Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. *World J Gastroenterol* 2006;12:603-607.

³⁰Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-697.

³¹Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991-4997.

³²Shah MA, Shibata S, Stoller RG, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). *J Clin Oncol (Meeting Abstracts)* 2010;28:4014-.

³³Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2008;19:1882-1887.

³⁴Ozal G, Dogan M, Akbulut H, et al. The safety and efficacy of modified-dose docetaxel, cisplatin, and 5-fluorouracil (mDCF) combination in the front-line treatment of advanced gastric cancer. [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium Abstract 113.

³⁵Roth AD, Fazio N, Stupp R, et al. Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. *J Clin Oncol* 2007;25:3217-3223.

³⁶Elkerm YM, Elsaid A, AL-Batran S, Pauligk C. Final results of a phase II trial of docetaxel-carboplatin-FU in locally advanced gastric carcinoma [abstract]. Presented at the Gastrointestinal Cancers Symposium 2008. Abstract 38.

³⁷Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996-2004.

³⁸Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36-46.

³⁹Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435-1442.

⁴⁰Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. *J Clin Oncol* 2004;22:4319-4328.

⁴¹Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009;20:666-673.

⁴²Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. *J Clin Oncol (Meeting Abstracts)* 2010;28:4006-.

⁴³Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2008;19:1450-1457.

⁴⁴Afchain P, Samalin E, Thezenas S, et al. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) in metastatic gastric adenocarcinoma (MGA) [abstract]. *J Clin Oncol* 2008;26(Suppl 15):Abstract 15539.

⁴⁵Wolff K, Wein A, Reulbach U, et al. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. *Anticancer Drugs* 2009;20:165-173.

⁴⁶Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. *Cancer J* 2000;6:316-323.

⁴⁷Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. *Br J Cancer* 1998;78:511-514.

⁴⁸Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. *Am J Clin Oncol* 2003;26:37-41.

⁴⁹Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667.

⁵⁰Kim JY, Do YR, Park KU, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. *Cancer Chemother Pharmacol* 2010;66:31-36.

⁵¹Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. *Ann Oncol* 2009;20:1242-1248.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

PRINCIPLES OF SYSTEMIC THERAPY--REFERENCES

⁵²Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54-59.

⁵³Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. *Ann Oncol* 2004;15:1344-1347.

⁵⁴Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. *Med Oncol* 2007;24:407-412.

⁵⁵Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 1994;86:1086-1091.

⁵⁶Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP.

Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. *Ann Oncol* 2007;18:898-902.

⁵⁷Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. *Oncology (Williston Park)* 2004;18:22-25.

⁵⁸Leary A, Assersohn L, Cunningham D, et al. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. *Cancer Chemother Pharmacol* 2009;64:455-462.

⁵⁹Di Lauro L, Fattoruso SI, Giacinti L, et al. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines [abstract]. *J Clin Oncol* 2009;27(Suppl 15):Abstract 4549.

⁶⁰Giuliani F, Molica S, Maiello E, et al. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). *Am J Clin Oncol* 2005;28:581-585.

⁶¹Bamias A, Papamichael D, Syrigos K, Pavlidis N. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. *J Chemother* 2003;15:275-281.

⁶²Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *J Clin Oncol (Meeting Abstracts)* 2009;27:4540-.

⁶³Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. *J Clin Oncol* 2003;21:807-814.

⁶⁴Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337-345.

⁶⁵Pipp M, Mulkerin D, Warren D, et al. A Phase II Trial of Gemcitabine and 5-Fluorouracil in Advanced Esophageal Cancer. [abstract]. Presented at the 2001 ASCO Annual Meeting Abstract 630.

⁶⁶Cascinu S, Galizia E, Labianca R, et al. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. *Cancer Chemother Pharmacol* 2010.

⁶⁷Lustberg MB, Bekaii-Saab T, Young D, et al. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. *J Thorac Oncol* 2010;5:713-718.

⁶⁸Hofheinz RD, Hartung G, Samel S, et al. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study. *Onkologie* 2002;25:255-260.

⁶⁹Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. *J Clin Oncol* 2000;18:2648-2657.

⁷⁰Taal BG, Teller FG, ten Bokkel Huinink WW, et al. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. *Ann Oncol* 1994;5:90-92.

⁷¹Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127. *J Clin Oncol* 2006;24:4922-4927.

⁷²Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. *Cancer* 2010.

⁷³Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. *ASCO Meeting Abstracts* 2008;26:4536-.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF RADIATION THERAPY

General Radiation Information

- Prior to simulation, pertinent radiographs, procedure notes and pathology reports should be reviewed by a multidisciplinary team including surgical, radiation, medical oncologists, gastroenterologists, radiologists and pathologists. This will allow an informed determination of treatment volume and field borders prior to simulation.

Simulation and Treatment Planning

- Use of CT simulation and 3D treatment planning is strongly encouraged.
- The patient should be instructed to avoid intake of a heavy meal for 3 hours before simulation and treatment. When clinically appropriate, use of IV and/or oral contrast for CT simulation may be used to aid in target localization.
- Use of an immobilization device is strongly recommended for reproducibility of daily set-up.
- All patients should be simulated and treated in the supine position.
- Although AP/PA fields can be weighted anteriorly to keep the spinal cord dose at acceptable levels using only parallel-opposed techniques, a 4-field technique (AP/PA and opposed laterals), if feasible, can spare spinal cord with improved dose homogeneity. Patients with a stomach that is sufficiently anterior to allow treatment via laterals to the target volume and draining lymph nodes with 1.5-2 cm margin while sparing spinal cord may have more liberal use of lateral beams with multiple-field techniques. The uncertainties arising from variations in stomach filling and respiratory motion should also be taken into consideration.
- With the wide availability of 3D treatment-planning systems, it may be possible to target more accurately the high-risk volume and to use unconventional field arrangements to produce superior dose distributions. To accomplish this without marginal misses, it will be necessary to both carefully define and encompass the various target volumes because the use of oblique or non-coplanar beams could exclude target volumes that would be included in AP/PA fields or multiple-field techniques.

Simulation and Treatment Planning---continued

- Intensity modulated radiation therapy (IMRT) may be appropriate in selected cases to reduce dose to normal structures such as heart, lungs, kidneys and liver. As discussed above, target volumes need to be carefully defined and encompassed while designing IMRT plans. Uncertainties from variations in stomach filling and respiratory motion need to be taken into account. For structures such as the lungs, attention should be given to the volume receiving low to moderate doses, as well as the volume receiving high doses.

Target Volume (General Guidelines)

- Preoperative¹
 - Pre-treatment diagnostic studies (EUS, UGI, EGD, and CT scans) should be used to identify the tumor and pertinent nodal groups.^{2,3} The relative risk of nodal metastases at a specific nodal location is dependent on both the site of origin of the primary tumor and other factors including width and depth of invasion of the gastric wall.
- Postoperative⁴
 - Pre-treatment diagnostic studies (EUS, UGI, EGD, and CT scans) and clip placement should be used to identify the tumor/gastric bed, the anastomosis or stumps, and pertinent nodal groups.^{2,3} Treatment of the remaining stomach should depend on a balance of the likely normal tissue morbidity and the perceived risk of local relapse in the residual stomach. The relative risk of nodal metastases at a specific nodal location is dependent on both the site of origin of the primary tumor and other factors including width and depth of invasion of the gastric wall.⁵

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**PRINCIPLES OF RADIATION THERAPY****Proximal one-third/Cardia/Esophagogastric Junction Primaries**

- **Preoperative and Postoperative**
 - **With proximal gastric lesions or lesions at the EG junction, a 3- to 5-cm margin of distal esophagus, medial left hemidiaphragm and adjacent pancreatic body should be included. Nodal areas at risk include: adjacent paraesophageal, perigastric, suprapancreatic, and celiac lymph nodes.**

Middle one-third/Body Primaries

- **Preoperative and Postoperative**
 - **Body of pancreas should be included. Nodal areas at risk include: perigastric, suprapancreatic, celiac, splenic hilar, porta hepatic, and pancreaticoduodenal lymph nodes.**

Distal one-third/Antrum/Pylorus Primaries

- **Preoperative**
 - **Head of pancreas, 1st and 2nd part of duodenum should be included if the gross lesion extended to the gastroduodenal junction. Nodal areas at risk include: perigastric, suprapancreatic, celiac, porta hepatic, and pancreaticoduodenal lymph nodes.**
- **Postoperative**
 - **Head of pancreas, a 3- to 5-cm margin of duodenal stump should be included if the gross lesion extended to the gastroduodenal junction. Nodal areas at risk include: perigastric, suprapancreatic, celiac, porta hepatic, and pancreaticoduodenal lymph nodes.**

Blocking

- **Custom blocking is necessary to reduce unnecessary dose to normal structures including liver (60% of liver < 30 Gy), kidneys (at least 2/3 of one kidney < 20 Gy), spinal cord (< 45 Gy), heart (1/3 of heart < 50 Gy, effort should be made to keep the left ventricle doses to a minimum) and lungs.^a**

Dose

- **45-50.4 Gy (1.8 Gy/day)**

Supportive Therapy

- **Treatment interruptions or dose reductions for manageable acute toxicities should be avoided. Careful patient monitoring and aggressive supportive care are preferable to treatment breaks.**
- **During radiation treatment course, patients should be seen for status check at least once a week with notation of vital signs, weight and blood counts.**
- **Antiemetics should be given on a prophylactic basis, and antacid and antidiarrheal medications may be prescribed when needed.**
- **If estimated caloric intake is < 1500 kcal/day, oral and/or enteral nutrition should be considered. When indicated, feeding jejunostomies (J-tube) or nasogastric feeding tubes may be placed to ensure adequate caloric intake. During surgery, a J-tube may be placed for postoperative nutritional support.**
- **B₁₂, iron, and calcium level should be closely monitored, especially for postoperative patients. Monthly B₁₂ shots may be needed because of loss of intrinsic factor. Iron absorption is reduced without gastric acid. Oral supplementation, given with acid such as orange juice, can often maintain adequate levels. Calcium supplementation should also be encouraged.**
- **Adequate enteral and/or IV hydration is necessary throughout chemoradiation and early recovery.**

^aLung Dose Volume Histogram (DVH) parameters as predictors of pulmonary complications in gastric/esophagogastric junction cancer patients treated with concurrent chemoradiotherapy should be strongly considered, though consensus on optimal criteria has not yet emerged. Every effort should be made to keep the lung volume and doses to a minimum. Treating physicians should be aware that the DVH reduction algorithm is hardly the only risk factor for pulmonary complications. DVH parameters as predictors of pulmonary complications in gastric/esophagogastric junction cancer patients are an area of active development among the NCCN institutions and others.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[References on next page](#)

GAST-F
2 of 3



PRINCIPLES OF RADIATION THERAPY

- ¹Ajani AJ, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. *JCO* 2006;24:3953-3958.
- ²Willett CG, Gunderson LL. Stomach, in: Perez and Brady's principles and practice of radiation oncology, 5th ed. Lippincott Williams & Wilkins, 2007;1318-1335.
- ³Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. *Int J Radiat Oncol Biol Phys* 2002;52:283-293.
- ⁴Macdonald JS, Smalley S, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 345:725-730, 2001.
- ⁵Tepper JE, Gunderson LE, Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. *Semin Radiat Oncol* 2002;12(2):187-195.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF BEST SUPPORTIVE CARE

The goal of best supportive care is to prevent and relieve suffering and to support the best possible quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies. For gastric cancer, interventions undertaken to relieve major symptoms may result in prolongation of life. This appears to be particularly true when a multimodality interdisciplinary approach is pursued, and therefore, a multimodality interdisciplinary approach to palliative care of the gastric cancer patient is encouraged.

Bleeding

- Bleeding is common in patients with gastric cancer and may directly arise from the tumor, or as a consequence of therapy. Patients with acute severe bleeding (hematemesis or melena) should undergo prompt endoscopic assessment.¹
 - ▶ Endoscopic hemostatic interventions appropriate to the findings should be carried out
 - ▶ Interventional radiology angiographic embolization techniques may be useful in those situations where endoscopy is not helpful
 - ▶ External beam radiation therapy²
- Chronic blood loss from gastric cancer
 - ▶ External beam radiation therapy²

Obstruction

- Endoscopic relief of obstruction
 - ▶ Balloon dilation
 - ▶ Placement of enteral stent for relief of outlet obstruction,³ or esophageal stent for EGJ/cardia obstruction (see [NCCN Esophageal or Esophagogastric Cancer Guidelines](#))
- Surgery
 - ▶ Gastrojejunal bypass³
 - ▶ Gastrectomy in select patients⁴
- Establish enteral access for purposes of hydration and nutrition if endoscopic lumen enhancement is not undertaken or is unsuccessful
 - ▶ Feeding percutaneous endoscopic gastrostomy for patients with EGJ/cardia obstruction if tumor location permits
 - ▶ Endoscopic or surgical placement of jejunal feeding tube for patients with mid and distal gastric obstruction
- Venting gastrostomy
 - ▶ Percutaneous endoscopic gastroscopy for gastric decompression in patients with gastric outlet obstruction if tumor location permits
 - ▶ Interventional radiology placement of venting gastrostomy
- External beam radiation therapy
- Chemotherapy^a

^a[See Principles of Systemic Therapy \(GAST-E\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF BEST SUPPORTIVE CARE

Pain

- External beam radiation therapy²
- Chemotherapy^a
- If patient is experiencing tumor related pain, then the pain should be assessed and treated in accordance with the [PAIN-1](#) section of the [NCCN Adult Cancer Pain Guidelines](#).
- Severe uncontrolled pain following gastric stent placement should be treated emergently with endoscopic removal of the stent once uncontrollable nature of pain is established.

Nausea/Vomiting

- If patient is experiencing nausea and vomiting, then the patient should be treated in accordance with the [NCCN Antiemesis Guidelines](#).
- Nausea and vomiting may be associated with luminal obstruction, so endoscopic or fluoroscopic evaluation should be performed to determine if luminal enhancement is indicated.

^a[See Principles of Systemic Therapy \(GAST-E\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF BEST SUPPORTIVE CARE
(References)

- ¹Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. *J Support Oncol.* 2005;3(2):101-110.
- ²Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. *Acta Oncol.* 2008;47(3):421-427.
- ³Jeurnink SM, van Eijck CH, Steyerberg EW, Kuipers EJ, Siersema PD. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol.* 2007;7:18.
- ⁴Lim S, Muhs BE, Marcus SG, Newman E, Berman RS, Hiotis SP. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? *J Surg Oncol.* 2007;95(2):118-122.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



Table 1

**American Joint Committee on Cancer (AJCC)
TNM Staging Classification for Carcinoma of the Stomach
(7th ed., 2010)**

Primary Tumor (T)

- TX Primary tumor cannot be assessed
- T0 No evidence of primary tumor
- Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria
- T1 Tumor invades lamina propria, muscularis mucosae or submucosa
 - T1a Tumor invades lamina propria or muscularis mucosae
 - T1b Tumor invades submucosa
- T2 Tumor invades muscularis propria*
- T3 Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures**,***
- T4 Tumor invades serosa (visceral peritoneum) or adjacent structures**,***
 - T4a Tumor invades serosa (visceral peritoneum)
 - T4b Tumor invades adjacent structures

Regional Lymph Nodes (N)

- NX Regional lymph node(s) cannot be assessed
- N0 No regional lymph node metastasis§
- N1 Metastasis in 1 - 2 regional lymph nodes
- N2 Metastasis in 3 - 6 regional lymph nodes
- N3 Metastasis in seven or more regional lymph nodes
 - N3a Metastasis in 7 - 15 regional lymph nodes
 - N3b Metastasis in 16 or more regional lymph nodes

Distant Metastasis (M)

- M0 No distant metastasis
- M1 Distant metastasis

Histologic Grade (G)

- GX Grade cannot be assessed
- G1 Well differentiated
- G2 Moderately differentiated
- G3 Poorly differentiated
- G4 Undifferentiated

* Note: A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified T4.

**The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.

***Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach.

§A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined.

[Continued...](#)

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC (SBM). (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

**Table 1 - Continued****American Joint Committee on Cancer (AJCC)****TNM Staging Classification for Carcinoma of the Stomach****(7th ed., 2010)****Anatomic Stage/Prognostic Groups**

Stage 0	Tis	N0	M0
Stage IA	T1	N0	M0
Stage IB	T2	N0	M0
	T1	N1	M0
Stage IIA	T3	N0	M0
	T2	N1	M0
	T1	N2	M0
Stage IIB	T4a	N0	M0
	T3	N1	M0
	T2	N2	M0
	T1	N3	M0
Stage IIIA	T4a	N1	M0
	T3	N2	M0
	T2	N3	M0
Stage IIIB	T4b	N0	M0
	T4b	N1	M0
	T4a	N2	M0
	T3	N3	M0
Stage IIIC	T4b	N2	M0
	T4b	N3	M0
	T4a	N3	M0
Stage IV	Any T	Any N	M1

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and Business Media LLC (SBM). (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 05/25/10

NCCN Categories of Evidence and Consensus

Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

Category 3: The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

Cancers originating in the esophagus, gastroesophageal (GE) junctions, and stomach, constitute a major health problem around the world. An estimated 37,600 new cases of and 25,150 deaths from upper gastrointestinal (GI) cancers will occur in the United States in 2009.¹ A dramatic shift in the location of upper GI tumors has occurred in the United States.² Changes in histology and location of upper GI tumors have also been observed in some parts of Europe.^{3,4} In countries in the Western Hemisphere, the most common sites of gastric cancer are the proximal lesser curvature, in the cardia, and the GE junction.² It is possible that in the coming decades these changing trends will also occur in South America and Asia.

Epidemiology

Gastric cancer is rampant in many countries around the world. In Japan, it remains the most common type of cancer among men. More new cases of gastric cancer are diagnosed in China each year than any other country. The incidence of gastric cancer, however, has been declining globally since World War II and it is one of the least common cancers in North America. By some estimates, it is the fourth most common cancer worldwide.⁵ In 2009, an estimated 21,130 new cases will be diagnosed and 10,620 cases will eventually die of their disease in United States.¹ In developed countries, the incidence of gastric cancer originating from the cardia follows the distribution of esophageal cancer.⁶⁻⁸ Non-cardia gastric adenocarcinoma shows marked geographic variation with countries such as Japan, Korea, China, Taiwan, Costa Rica, Peru, Brazil, Chile and the former Soviet Union show a high incidence of the cancer.⁹ In contrast to the incidence trends in the West, non-proximal tumors continue to predominate in Japan and other parts of the world.¹⁰ The etiology of this shift remains elusive and may be multifactorial.

Gastric cancer is often diagnosed at an advanced stage. In Japan (and in a limited fashion in Korea) where screening is performed widely, early detection is often possible. In other parts of the world, it continues to pose a major challenge for healthcare professionals. Environmental risk factors include *Helicobacter pylori* (*H. pylori*) infection, smoking, high salt intake, and other dietary factors. Patients with a family history of non-hereditary gastric cancer have a higher risk of developing gastric cancer. In a limited number of patients (1% to 3%), its diagnosis is associated with inherited syndromes. E-cadherin mutations occur in approximately 25% of families with an autosomal dominant of a hereditary form of diffuse gastric cancer.¹¹ Genetic counseling is recommended and a consideration should be given to prophylactic

gastrectomy in young, asymptomatic carriers of germ-line truncating CDH1 mutations who belong to families with highly penetrant hereditary diffuse gastric cancer.¹²

Staging

Two major classifications are currently used. The Japanese classification is more elaborate and is based on anatomic involvement, particularly the lymph node stations.¹³ The other staging system developed jointly by the American Joint Committee on Cancer (AJCC) and the International Union against Cancer (UICC), is the system used in countries in the Western Hemisphere.¹⁴ A minimum of 15 examined lymph nodes is recommended for adequate staging.

Clinical baseline stage provides useful information for the development of an initial therapeutic strategy. Approximately 50% of patients will present with advanced disease at diagnosis and have a poor outcome. Other measures of poor outcome include poor performance status, presence of metastases, and alkaline phosphatase level of 100 U/L or more.¹⁵ In patients with localized resectable disease, outcome depends on the surgical stage of the disease. Nearly 70-80% of have involvement of the regional lymph nodes. The number of positive lymph nodes has a profound influence on survival.¹⁶

Preoperative Staging

Clinical staging has greatly improved with the availability of diagnostic modalities such as endoscopic ultrasound (EUS), computed tomography (CT), combined positron emission tomography PET-CT, magnetic resonance imaging (MRI) and laparoscopic staging.¹⁷⁻¹⁹

CT scan is routinely used for preoperative staging. It has an overall accuracy of 43% to 82% for T staging. PET-CT has a low detection rate because of the low tracer accumulation in diffuse and mucinous tumor

types which are frequent in gastric cancer.²⁰ It has a significantly lower sensitivity compared to CT in the detection of local lymph node involvement (56% vs.78%), although it has an improved specificity (92% vs. 62%).²¹ Combined PET-CT imaging, on the other hand, has several potential advantages over PET scan alone.²² PET-CT has a significantly higher accuracy in preoperative staging (68%) than PET (47%) or CT (53%) alone. Recent reports have confirmed that PET alone is not an adequate diagnostic procedure in the detection and preoperative staging of gastric cancer but it could be helpful when used in conjunction with CT.^{23, 24}

EUS is indicated for assessing the depth of tumor invasion.²⁵ The accuracy of EUS for T-staging ranges from 65% to 92% and 50% to 95% for N staging and is operator dependent. Distant lymph node evaluation by EUS is suboptimal given the limited depth and visualization of the transducer.²⁶

Laparoscopic staging can detect occult metastases. In a study conducted by Memorial Sloan Kettering Cancer Center, 657 patients with potentially resectable gastric adenocarcinoma underwent laparoscopic staging over a period of 10 years.²⁷ Distant metastatic disease (M1) was detected in 31% of the patients. Limitations of laparoscopic staging include two-dimensional evaluation and limited use in the identification of hepatic metastases and perigastric lymph nodes.

Indications for the use of laparoscopic staging differ among various NCCN institutions. In some, laparoscopic staging is reserved for medically fit patients with potentially resectable disease, specifically when consideration is made for chemoradiotherapy or surgery. In medically unfit patients, laparoscopy may still be considered especially if there is consideration for adding radiation to chemotherapy. The

guidelines have included laparoscopic staging with a category 2B recommendation.

Cytogenetic analysis of peritoneal fluid can help improve staging through identification of occult carcinomatosis.¹⁷ Reports in literature suggest that positive findings on peritoneal cytology is an independent predictor for identifying patients who are at higher risk for recurrence following curative resection.^{28, 29}

Surgery

Surgery is the primary treatment for early stage gastric cancer. Complete resection with adequate margins (4 cm or greater) is widely considered as a standard goal, whereas the type of resection (subtotal versus total gastrectomy) along with extent of lymphadenectomy remains a subject of controversy.

Principles of Surgery

The primary goal of surgery is to accomplish a complete resection with negative margins (R0 resection). Only 50% of patients will end up with an R0 resection of their primary.^{30, 31} As a reminder, R1 indicates microscopic residual disease (positive margins); and R2 indicates gross (macroscopic) residual disease in the absence of distant metastasis.³²

Subtotal gastrectomy is the preferred approach for distal gastric cancers. This procedure has a similar surgical outcome compared to total gastrectomy although with significantly fewer complications.³³

Proximal gastrectomy and total gastrectomy are both indicated for proximal gastric cancers and are typically associated with postoperative nutritional impairment.

Clinical staging using CT scan with or without EUS should be performed before surgery to assess the extent of the disease. Proximal

and distal margins of 4 cm or greater from the gross tumor are preferred.³⁴ The guidelines recommend distal, subtotal or total gastrectomy for T1b-T3 tumors. T4 tumors require en bloc resection of involved structures. Routine or prophylactic splenectomy should be avoided if possible. In a randomized clinical study, postoperative mortality and morbidity rates were slightly higher in patients who underwent total gastrectomy combined with splenectomy, and marginally better survival, but there were no statistically significant differences between the groups.³⁵ The results of this study do not support the use of prophylactic splenectomy to remove macroscopically negative lymph nodes near the spleen in patients undergoing total gastrectomy for proximal gastric cancer. Placement of a jejunostomy feeding tube may be considered for selected patients who will be receiving postoperative chemoradiation.

Carcinomas are considered unresectable if there is evidence of peritoneal involvement, distant metastases, or locally advanced disease such as (invasion or encasement of major blood vessels. Limited gastric resection, even with positive margins is acceptable for unresectable tumors for symptomatic palliation of bleeding. Palliative gastric resection should not be performed unless the patient is symptomatic and lymph node dissection is not required. Gastric bypass with gastrojejunostomy to the proximal stomach may be useful for the palliation of obstructive symptoms in symptomatic patients. Placement of venting gastrotomy and/or a feeding jejunostomy tube may be considered.

Lymph Node Dissection

Gastric resection may be classified by the extent of lymph node dissection at surgery. The extent of lymph node dissection remains controversial. The Japanese Research Society for the Study of Gastric

Cancer has established guidelines for pathologic examination and evaluation of lymph node stations that surround the stomach.³⁶ The perigastric lymph node stations along the lesser curvature (stations 1, 3, and 5) and greater curvature (stations 2, 4, and 6) of the stomach are grouped together as N1. The nodes along the left gastric artery (station 7), common hepatic artery (station 8), celiac artery (station 9), and splenic artery (stations 10 and 11) are grouped together as N2. More distant nodes, including para-aortic (N3 and N4), are regarded as distant metastases. D0 dissection refers to incomplete resection of N1 lymph nodes. D1 dissection involves the removal of the involved proximal or distal part of the stomach or the entire stomach (distal or total resection), including the greater and lesser omental lymph nodes. The omental bursa along with the front leaf of the transverse mesocolon is removed and the corresponding arteries are cleared completely in a D2 dissection. A splenectomy (to remove stations 10 and 11) is required for a D2 dissection for proximal gastric tumors. The technical aspects of performing a D2 dissection require a significant degree of training and expertise.

A recent retrospective analysis has shown that more extensive lymph node dissection and analysis influences survival in patients with advanced gastric cancer. This analysis included 1,377 patients diagnosed with advanced gastric cancer in the Surveillance Epidemiology and End Results (SEER) database. Patients who had more than 15 N2 nodes and more than 20 N3 nodes examined had the best long-term survival outcomes.³⁷

Gastrectomy with D2 lymphadenectomy is the standard treatment for curable gastric cancer in eastern Asia. In a randomized controlled trial (JCOG9501), Japanese investigators comparing D2 lymphadenectomy alone with D2 lymphadenectomy with para-aortic nodal dissection (PAND) in patients undergoing gastrectomy for curable (T2b, T3 or T4)

gastric cancer reported a postoperative mortality rate of 0.8% in each arm.³⁸ The final results of this study showed that D2 lymphadenectomy with PAND does not improve survival rate in curable gastric cancer, compared to D2 lymphadenectomy alone. The 5-year overall survival (OS) rates were 70.3% and 69.2% respectively. There were also no significant differences in the relapse-free survival (RFS) rates between the two groups.³⁹ In a post hoc subgroup analysis, the survival rates were better among patients with pathologically negative nodes assigned to D2 lymphadenectomy plus PAND than those who were assigned to D2 lymphadenectomy alone, whereas in patients with metastatic nodes, the survival rates were worse for those assigned to D2 lymphadenectomy plus PAND. However, the investigators of this study caution that these results from post hoc analysis could be false positive due to multiple testing and the survival benefit of D2 lymphadenectomy plus PAND in node-negative patients need to be clarified in further studies. The investigators concluded that D2 lymphadenectomy plus PAND should not be used to treat patients with curable (T2b, T3 or T4) gastric cancer.

Japanese investigators have often emphasized the value of extensive lymphadenectomy (D2 and above). However, Western investigators have not found a survival advantage when extensive lymphadenectomy is compared with a D1 resection.⁴⁰⁻⁴³

In the Dutch Gastric Cancer Group Trial, 711 patients who underwent surgical resection with curative intent were randomized to undergo either a D1 or D2 lymphadenectomy.⁴² Both the postoperative morbidity (25% vs. 43%, $P < .001$) and mortality (4% vs. 10%, $P = .004$) were higher for patients who underwent D2 dissection, with no difference in OS (30% vs. 35%, $P = .53$) between the two groups. In a subset analysis, patients with N2 cancer undergoing a D2 lymphadenectomy showed a trend towards improved survival. Unfortunately, N2 cancer



can only be detected after microscopic examination of the surgical specimen.

The British Cooperative trial conducted by the Medical Research Council also failed to demonstrate a survival benefit for D2 over D1 lymphadenectomy.⁴¹ The 5-year OS rates were 35% for D1 dissection and 33% for D2 dissection. In addition, the D2 dissection was associated with increased postoperative morbidity and mortality. Both these trials found that splenectomy and pancreatectomy performed along with the D2 dissection significantly increased the mortality and morbidity.

Despite these results, interest in extended lymph node dissections (D2 and greater) has not waned.⁴⁴ Investigators have argued that if the complication rate after a D2 dissection could be decreased then there may be a benefit in selected patients. A surgical option that may decrease morbidity and mortality is a modified D2 lymphadenectomy without pancreatectomy and splenectomy.⁴⁵⁻⁴⁸

The phase II study conducted by the Italian Gastric Cancer Study Group (IGCSG) reported a survival benefit of pancreas-preserving D2 lymphadenectomy when performed in experienced cancer centers.^{49, 50} The 5-year OS rate among all eligible patients was 55%. The overall 5-year morbidity rate was 20.9% and a postoperative in-hospital mortality rate was 3.1% for D2 dissection without pancreatectomy.⁵⁰ These rates are comparable to the rates for D1 dissections in the Dutch and United Kingdom trial. The inclusion of pancreatectomy and splenectomy in D2 dissection resulted in increased morbidity and mortality.

Other reports from Western countries have also shown better outcomes for D2 lymphadenectomy when performed according to the

recommendations of Japanese Research Society of Gastric cancer. In an Austrian study, 5-year and 10-year OS rates were 45.7% and 34.3% respectively.⁵¹ For patients who underwent curative surgery, 5-year and 10-year survival rates were 57.7% and 44.3% respectively, which are comparable to those reported in Japanese trials. Postoperative mortality rates for R0, R1-R2 and palliative resections were 4.9%, 9% and 13.4% respectively. We recognize that cross-trial comparisons result in weak evidence and conclusions.

Sierra and colleagues from a single institution in Spain reported longer 5-year survival rates in the D2 group (50.6%) than the D1 group (41.4%).⁵² No significant differences were seen in morbidity (48.2% for D1 and 53.5% for D2). Operative mortality was 2.3% for D1 and 0% for D2 dissection. Pancreatectomy, hepatic wedge resection or partial colectomy was performed only for macroscopic invasion.

In a recent analysis involving patients from the Intergroup 0116 adjuvant chemoradiation trial, Enzinger and colleagues assessed the impact of hospital volume on the outcome of patients who underwent lymphadenectomy.⁵³ Patients were stratified into two groups: those who underwent D0 dissection (54%) and those who underwent D1 or D2 resection (46%). For patients who underwent D0 dissection, high-volume centers did not have any effect on OS or disease-free survival (DFS). However, there was a trend toward improved OS among patients who underwent D1 or D2 dissection at moderate to high volume cancer centers.

In the West, D2 dissection is considered a recommended but not required operation. Modified D2 lymphadenectomy (without pancreatectomy and splenectomy) is associated with low mortality and reasonable survival times when performed in institutions that have

sufficient experience with the operation and postoperative management.

The panel recommends that gastric cancer surgery should be performed by experienced surgeons in high volume cancer centers and should include removal of perigastric lymph nodes (D1) and those along the named vessels of the celiac axis (D2), with a goal of examining 15 or greater lymph nodes.

Endoscopic mucosal resection

Endoscopic mucosal resection (EMR) represents a major advance in minimally invasive surgery for gastric cancer. EMR has been used for patients with early gastric cancer (Tis or T1a tumors limited to mucosa).^{54, 55} Node-negative T1 tumors require limited resection since the 5-year survival rate is more than 90%.⁵⁶ Most of the experience with EMR for early gastric cancer has been gained by countries with a high incidence of gastric cancer and an active screening program.⁵⁷ The applicability of these techniques in the United States is limited because of the low incidence of early gastric cancer. Indications for EMR include well-differentiated or moderately differentiated histology, tumors less than 30 mm in size, absence of ulceration and no evidence of invasive findings.⁵⁸ No randomized studies have compared EMR with other surgical techniques for GI cancers. Nevertheless, EMR continues to evolve as a promising technology in the diagnosis and treatment of early esophageal and gastric cancers. Since long-term follow-up and survival data are lacking, the routine use of endoscopic techniques is not recommended outside a clinical trial and should be limited to medical centers with extensive experience.

Proper patient selection is essential when employing endoscopic or limited gastric resections (wedge). The probability of lymph node metastasis in early gastric cancer is influenced by tumor factors and is

increased with increasing tumor size, submucosal invasion, poorly differentiated tumors, and lymphatic and vascular invasion.⁵⁹ Tis or T1 tumors limited to mucosa (T1a) may be candidates for EMR in experienced centers.

Laparoscopic Resection

Laparoscopic resection is an emerging surgical approach which offers important advantages (less blood loss, reduced postoperative pain, accelerated recovery, early return to normal bowel function and reduced hospital stay) when compared with open surgical procedures for patients with gastric cancer.⁶⁰ A prospective randomized study conducted by Hulscher and colleagues compared early and 5-year clinical outcomes of laparoscopic and open subtotal gastrectomy in 59 patients with distal gastric cancer.⁶¹ Operative mortality rates (3.3% vs. 6.7% respectively), 5-year OS rates (58.9% vs. 55.7% respectively) and DFS rates (57.3% vs. 54.8% respectively) were better (though not significant) for the laparoscopic group. However, the role of this approach in the treatment of gastric cancer requires further investigation in larger randomized clinical trials.

Radiation Therapy

Radiation therapy (RT) has been assessed in randomized trials in both preoperative and postoperative setting in patients with resectable gastric cancer. Smalley and colleagues have reviewed clinical and anatomic issues related RT and offer detailed recommendations for the application of RT for the management of patients with resected gastric cancer.⁶²

In a randomized trial conducted by Zhang and colleagues, there was a significant improvement in survival with preoperative radiation (30% vs. 20%, $P = .0094$).⁶³ Resection rates were higher in the preoperative

radiation arm (89.5%) compared to surgery alone (79%), suggesting that preoperative radiation improves local control and survival. However, randomized trials are needed to confirm these results in patients from the Western Hemisphere.

In the trial conducted by the British Cancer Stomach Group, 432 patients were randomized to undergo surgery alone or surgery followed by RT or chemotherapy.⁶⁴ At 5-year follow-up, no survival benefit was seen for patients receiving postoperative RT or chemotherapy compared with those who underwent surgery alone. This trial also showed a significant reduction in locoregional relapse with the addition of RT to surgery (27% with surgery vs. 10% for adjuvant RT and 19% for adjuvant chemotherapy). The results from a recent systematic review and meta-analysis showed a statistically significant 5-year survival benefit with the addition of radiotherapy in patients with resectable gastric cancer.⁶⁵

External-beam RT (45-50.4 Gy) as a single modality has minimal value in palliating locally unresectable gastric cancer and does not improve survival.⁶⁶ However, when used concurrently with 5-fluorouracil, external-beam RT improves survival. Moertel and colleagues assessed 5-fluorouracil plus RT compared with RT alone in the treatment of locally unresectable gastric cancer.⁶⁷ Patients receiving combined modality treatment had a significantly better median survival (13 vs. 6 months) and 5-year OS (12% vs. none).

In another study by the Gastrointestinal Tumor Study Group (GITSG), 90 patients with locally advanced gastric cancer were randomized to receive either combination chemotherapy with 5-fluorouracil and methyl-CCNU (Iomustine) or split-course RT with a concurrent intravenous bolus of 5-fluorouracil followed by maintenance 5-fluorouracil and methyl-CCNU.⁶⁸ In the first 12 months mortality was

higher in the combined modality group. At 3 years the survival curve reached a plateau in the combined modality arm, but tumor-related deaths continued to occur in the chemotherapy-alone arm, suggesting that a small fraction of patients can be cured with combined modality treatment. In most of the randomized trials, combined modality treatment showed advantage over RT alone in relatively few patients with unresectable cancer, as reviewed by Hazard and colleagues.⁶⁶

Intensity modulated radiation therapy (IMRT) has great potential to reduce radiation-related toxicity by delivering large doses of radiation to target tissues.⁶⁹ The use of this technique in gastric cancer remains investigational and the impact of new conformal radiotherapy technologies needs to be assessed in randomized clinical trials.

Principles of Radiation Therapy

RT (preoperative, postoperative or palliative) can be an integral part of treatment for gastric cancer. All patients should be simulated and treated in the supine position. The panel encourages the use of CT simulation and 3D treatment planning. Intravenous and/or oral contrast may be used when appropriate for CT simulation to aid target localization. Use of an immobilization device is strongly recommended for reproducibility.

The panel recommends involvement of a multidisciplinary team, which should include medical, radiation and surgical oncologists, radiologists, gastroenterologists and pathologists to determine optimal diagnostic, staging and treatment modalities. Pretreatment diagnostic studies such as EUS, upper GI endoscopy and CT scans should be used to identify tumor and pertinent nodal groups. The relative risk of nodal metastases at a specific location is dependent on the location of the primary tumor and the extent of invasion of the gastric wall. It may be possible to accurately target high-risk areas and to produce superior dose

distributions with the use of 3D treatment planning systems and unconventional field arrangements. To accomplish this, it is necessary to carefully define and encompass various target volumes.

The panel recommends a dose range of 45-50.4 Gy delivered in fractions of 1.8 Gy per day. Every effort should be made to reduce unnecessary radiation doses to vital organs such as liver, kidneys, spinal cord, heart (especially the left ventricle) and lungs. Lung dose volume histogram (DVH) parameters should be considered as predictors of pulmonary complications in patients with gastric and GE junction cancers treated with concurrent chemoradiation, though optimal criteria have not yet emerged. Optimal criteria for DVH parameters are being actively developed in NCCN institutions.

Close patient monitoring and aggressive supportive care are essential during radiation treatment. Management of acute toxicities is necessary to avoid treatment interruptions or dose reductions. Antiemetics should be given on a prophylactic basis when appropriate. Antacid and antidiarrheal medications may be prescribed when needed. If the caloric intake is inadequate, enteral and/or parenteral nutrition should be considered. Oral and/or intravenous hydration is often necessary throughout chemoradiation and early recovery. Feeding jejunostomies may be placed if clinically indicated. It is essential to monitor levels of B₁₂, iron and calcium in postoperative patients. Oral supplementation is recommended to maintain adequate levels.

Combined Modality Treatment: Concomitant Chemotherapy and Radiation Therapy

Preoperative Chemoradiation Therapy

In a pilot study, Lowy and colleagues assessed the feasibility of preoperative chemoradiation (45 Gy of external beam RT with

concurrent continuous infusion of 5-fluorouracil) followed by surgery and IORT (10 Gy) in the treatment of patients with potentially resectable gastric cancer.⁷⁰ Significant pathologic responses were seen in 63% of patients and complete pathologic response was seen in 11% of patients who received preoperative chemoradiation. Eighty three percent of patients who received chemoradiation therapy underwent D2 lymphadenectomy.

Recent studies have also shown that preoperative induction chemotherapy followed by chemoradiotherapy yields a substantial pathologic response that results in durable survival time.⁷¹⁻⁷⁴ In the RTOG study, pathologic complete response was achieved in 26% of patients. D2 lymphadenectomy and R0 resection were achieved in 50% and 77% of patients respectively.⁷³ In a recent phase III study, Stahl et al. compared preoperative chemotherapy (cisplatin, fluorouracil and leucovorin) with chemoradiation therapy using the same regimen in 119 patients with locally advanced adenocarcinoma of the GE junction.⁷⁴ Patients with locally advanced adenocarcinoma of the lower esophagus or GE junction were randomized between two treatment groups: chemotherapy followed by surgery (arm A) or chemotherapy followed by chemoradiotherapy followed by surgery (arm B). Patients in arm B had a significantly higher probability of showing pathologic complete response (15.6% vs. 2.0%) or tumor-free lymph nodes (64.4% vs. 37.7%) at resection. Preoperative chemoradiation therapy improved 3-year survival rate from 27.7% to 47.4%. Although the study was closed prematurely due to low accrual and statistical significance was not achieved, there was a trend towards survival advantage for preoperative chemoradiotherapy compared with preoperative chemotherapy in adenocarcinomas of the GE junction. The value of preoperative chemoradiation therapy remains uncertain and needs to be determined in larger prospective randomized trials.

Postoperative Chemoradiation Therapy

Nonrandomized trials from Baeza and colleagues have reported encouraging results for patients with R0 resections who receive adjunctive treatment.⁷⁵ Limited reports from randomized trials of postoperative RT with or without chemotherapy after a complete resection with negative margins did not reveal a clear survival advantage.^{67, 76, 77}

The landmark trial is the Intergroup trial SWOG 9008/INT-0116.⁷⁸ In this trial 556 patients with adenocarcinoma of the stomach or GE junction [stage IB through stage IV (M0)] were randomly assigned to surgery only (n=275) or surgery plus chemoradiation (n=281). Patients were at high risk for relapse; more than two thirds of them had T3 or T4 tumors and 85% of patients had node positive disease.

Postoperative combined modality treatment consisting of five monthly cycles of bolus chemotherapy (5-fluorouracil and leucovorin) with RT (45 Gy) concurrent with cycles 2 and 3. There was a significant decrease in local failure as the first site of failure (19% vs. 29%) as well as an increase in median survival (36 vs. 27 months), 3-year RFS (48% vs. 31%), and OS (50% vs. 41%, $P = .005$) with combined modality treatment. With more than 10 years of median follow-up, survival remains improved in patients with stage IB-IV (M0) gastric cancer treated with postoperative chemoradiation. No increases in late toxic effects were noted.⁷⁹ Although gastric resection with extended lymph node dissection (D2) was recommended for all patients, only 10% of patients had the recommended D2 lymphadenectomy. D1 dissection was performed in 36% of the patients and 54% underwent D0 dissection. It should be noted that surgery was not part of this protocol and patients were eligible for the study only after recovery from surgery. Nevertheless, the results of this study have established postoperative chemoradiation therapy as

a standard of care in patients with resected gastric cancer who have not received preoperative therapy.

An ongoing large phase III trial (ARTIST) is comparing the effects of adjuvant chemoradiation (capecitabine and cisplatin plus RT) compared to adjuvant chemotherapy (capecitabine and cisplatin) after D2 resection of gastric cancer. The primary endpoint is 3-year DFS.⁸⁰

Chemotherapy

Perioperative Chemotherapy

The British Medical Research Council performed the first well-powered phase III trial (MAGIC trial) for perioperative chemotherapy.⁸¹ In this trial, 503 patients were randomized to receive either perioperative chemotherapy [preoperative and postoperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF)] and surgery or surgery alone. In each group, 74% of patients had stomach cancer, 14% had lower esophageal cancer and 11% had cancer of GE junction. The perioperative chemotherapy group had a greater proportion of pathologic T1 and T2 tumors (51.7%) than the surgery group (36.8%). Five-year survival rates were 36% among those who received perioperative chemotherapy and 23% in the surgery group. Perioperative chemotherapy with the ECF regimen significantly improved PFS and OS in patients with operable gastric and lower esophageal adenocarcinomas. The results of this study have established perioperative chemotherapy as another added option to the standard of care of for patients with resectable gastric cancer.

Postoperative chemotherapy

S-1 is a novel oral fluoropyrimidine which is a combination of tegafur (prodrug of 5-fluorouracil; 5-chloro-2,4-dihydropyridine) and oxonic acid.⁸² A large randomized phase III study (ACTS GC) in Japan

evaluated the efficacy of adjuvant chemotherapy with S-1 in patients with stage II (excluding T1) or stage III gastric cancer who underwent R0 gastric resection with extensive lymph-node dissection (D2).⁸³ This study randomized 1,059 patients to surgery followed by adjuvant treatment with S-1 or surgery alone. OS rate at 3 years was 80.1% and 70.1% for S-1 group and surgery alone respectively. Hazard ratio for death in the S-1 group was 0.68.

This is the first time adjuvant chemotherapy has been shown to be beneficial after D2 resection in the Japanese patient population. In an earlier randomized trial (579 patients) conducted by Japan Clinical Oncology Group (JCOG 8801), no significant survival benefit with adjuvant chemotherapy was seen with UFT (a combination of uracil and tegafur) after D2 resection.⁸⁴ There are no data available with S-1 in Western patients in this setting.

Chemotherapy for Advanced or Metastatic Disease

Chemotherapy can provide both palliation and improved survival in patients with advanced and metastatic disease. Single agents with activity in patients with advanced gastric cancer include 5-fluorouracil, mitomycin, etoposide, and cisplatin, with reported response rate ranging between 10% and 20%.^{85, 86} Other agents including irinotecan, paclitaxel, docetaxel, oral etoposide, oxaliplatin, UFT have shown activity as single agents and in combination in patients with advanced gastric cancer.⁸⁷⁻⁹⁸

Irinotecan as a single agent or in combination has been explored extensively in single arm and randomized clinical trials.⁹⁹⁻¹⁰⁸ The results of a randomized phase III study comparing irinotecan in combination with 5-fluorouracil and folinic acid to cisplatin combined with infusional 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or GE junction showed non-inferiority for progression-free

survival and improved tolerance of the irinotecan containing regimen, thus it can be alternative when platinum-based therapy cannot be delivered.¹⁰² Irinotecan, however, is best suited after front-line therapy.

In another randomized multicenter phase II study, Moheler et al. compared capecitabine combined with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or GE junction.¹⁰⁵ There were no significant differences in overall response rates (37.7% and 42.0% respectively), and median PFS (4.2 months and 4.8 months respectively), although there was a trend towards better median OS in the irinotecan arm (10.2 vs. 7.9 months). The results of this study need to be validated further in larger studies.

Chemotherapy resulted in an improved quality of life and OS compared to best supportive care in patients with advanced gastric cancer.^{109, 110} In the early 1980s, FAM (5-fluorouracil, doxorubicin, and mitomycin) was considered the gold standard for patients with advanced gastric cancer.¹¹¹ The pivotal study performed by the North Central Cancer Treatment Group (NCCTG) comparing FAM to 5-fluorouracil alone and 5-fluorouracil plus doxorubicin showed no significant survival difference between all 3 arms.¹¹² Higher response rates were observed in patients who received combination chemotherapy versus 5-fluorouracil alone.

In the past 3 decades, several randomized studies have compared FAM vs. FAMTX (5-fluorouracil, adriamycin, and methotrexate),¹¹³ FAMTX vs. ECF (epirubicin, cisplatin, and 5-fluorouracil),¹¹⁴ FAMTX vs. ELF (etoposide, leucovorin, and 5-fluorouracil) vs. 5-fluorouracil plus cisplatin,¹¹⁵ and ECF vs. MCF (mitomycin, cisplatin, 5-fluorouracil).¹¹⁶ ECF demonstrated improvements in median survival and quality of life when compared to FAMTX or MCF regimens. Recently, a phase III trial conducted by the German Study Group showed that the combination of fluorouracil, leucovorin and oxaliplatin (FLO) had a trend toward

improved median PFS compared to fluorouracil, leucovorin and cisplatin (FLP) (5.8 vs. 3.9 months).¹¹⁷ However, there were no significant differences in median OS (10.7 vs. 8.8 months, respectively) between the two groups. FLO was associated with significantly less toxicity than FLP. In patients older than 65 years, FLO resulted in significantly superior response rates (41.3% vs. 16.7%), time to treatment failure (5.4 vs. 2.3 months), PFS (6.0 vs. 3.1 months), and an improved OS (13.9 vs. 7.2 months) compared with FLP, respectively.

In a randomized multinational phase III study (V325), 445 untreated patients with advanced gastric cancer were randomized to receive either the combination of docetaxel, cisplatin and 5-fluorouracil (DCF) every 3 weeks or the combination of cisplatin and fluorouracil (CF).¹¹⁸ Time to progression was significantly longer with DCF compared with CF (5.6 vs. 3.7 months). In 2006, based on the results of this study, FDA (Food and Drug Administration) approved DCF regimen for the treatment of advanced gastric cancer, including cancer of the GE junction, in patients who have not received prior chemotherapy for advanced disease. Various modifications of DCF regimen with the intent to improve tolerability are being evaluated in clinical trials for patients with advanced gastric cancer.^{119, 120}

Capecitabine is an orally administered fluoropyrimidine which is converted to 5-fluorouracil intracellularly. Several studies have evaluated capecitabine in combination with other agents in patients with advanced esophagogastric cancers.¹²¹ Two phase III trials (REAL-2 and ML 17032) have assessed the efficacy and safety of capecitabine in gastric cancer.^{122, 123}

The REAL-2 (with 30% of patients having an esophageal cancer) trial was a randomized multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in 1003 patients with

advanced esophagogastric cancer.¹²² Patients with histologically confirmed adenocarcinoma, squamous or undifferentiated cancer of the esophagus, GE junction or stomach were randomized to receive one of the four epirubicin-based regimens [ECF, epirubicin, oxaliplatin, 5-fluorouracil (EOF), epirubicin, cisplatin and capecitabine (ECX) and epirubicin, oxaliplatin and capecitabine (EOX)]. Median follow-up was 17.1 months. Results from this study suggest that capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin respectively, in patients with previously untreated esophagogastric cancer. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy. The toxic effects from 5-fluorouracil and capecitabine were not different.

ML 17032, another phase III randomized trial, evaluated the combination of capecitabine and cisplatin (XP) versus the combination of 5-fluorouracil and cisplatin (FP) as first-line treatment in patients with previously untreated advanced gastric cancer.¹²³ Overall response rate (41% vs. 29%) and OS (10.5 months vs. 9.3 months) were superior for patients who received XP regimen. No difference in median PFS was seen for both regimens (5.6 months for XP and 5.0 months for FP). The results of this study suggest that capecitabine is as effective as 5-fluorouracil in the treatment of patients with advanced gastroesophageal cancers.

A meta-analysis of the REAL-2 and ML17032 trials suggested that OS was superior in the 654 patients treated with capecitabine-based combinations compared with the 664 patients treated with 5-fluorouracil-based combinations although no significant difference in PFS between treatment groups was seen.¹²⁴

Another novel oral fluoropyrimidine S-1 has shown promise in advanced gastric cancer, both as a single agent and in combination with cisplatin in early phase studies.¹²⁵⁻¹²⁷ In a randomized phase III trial (SPIRITS trial), 298 patients with advanced gastric cancer were randomized to S-1 plus cisplatin and S-1 alone. Median OS (13 vs. 11 months respectively) and PFS (6.0 vs. 4 months respectively) were significantly longer for the combination of S-1 and cisplatin compared with S-1 alone.¹²⁸ The combination of S-1 and cisplatin in patients with untreated advanced gastric cancer and GE junction adenocarcinoma was shown to be safe and active in a multicenter phase II trial conducted in the United States.^{129, 130}

The results of First Line Advanced Gastric Cancer Study (FLAGS) comparing the combination of cisplatin and S-1 (CS) with cisplatin and 5-fluorouracil (CF) in patients with advanced gastric/gastroesophageal adenocarcinoma was recently presented. In this study 1053 patients were randomized to either CS or CF.¹³¹ CS had similar efficacy compared to CF with improved safety. In a subset analysis, CS produced statistically superior OS for patients with diffuse type histology. Additional studies are needed to confirm the activity of S-1 in the US and western hemisphere.

Targeted Therapies

The overexpression of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and HER2 has been associated with poor prognosis in patients with gastric and esophageal cancers.^{132, 133} In clinical trials, trastuzumab (anti-HER2 antibody), bevacizumab (an anti-VEGFR antibody) and cetuximab (anti-EGFR antibody) have been evaluated in combination with chemotherapy in the treatment of patients with advanced gastric and GE junction adenocarcinoma.

The ToGA study is the first randomized, prospective, multicenter, phase III trial to evaluate the efficacy and safety of trastuzumab in HER2-positive gastric cancer in combination with cisplatin and a fluoropyrimidine.¹³⁴ The results of this study confirmed that trastuzumab plus standard chemotherapy is superior to chemotherapy alone in patients with HER2-positive advanced gastric cancer. Five hundred and ninety four patients with HER2-positive gastroesophageal and gastric adenocarcinoma (locally advanced, recurrent, or metastatic) were randomized to receive trastuzumab plus chemotherapy (5-fluorouracil or capecitabine and cisplatin) or chemotherapy alone. There was a significant improvement in the median OS with the addition of trastuzumab to chemotherapy compared to chemotherapy alone (13.5 vs. 11.1 months, respectively). Safety profiles were similar with no unexpected adverse events in the trastuzumab. There was also no difference in symptomatic congestive heart failure between arms. This establishes that trastuzumab plus chemotherapy as a new standard of care for the treatment of patients with a HER2-expressing advanced gastric and GE cancers.

The safety and efficacy of bevacizumab,^{135, 136} sorafenib,¹³⁷ and cetuximab,¹³⁸⁻¹⁴³ has been evaluated in multiple phase II studies. Ongoing phase III trials are underway to confirm the efficacy and safety of the above mentioned agents in combination with standard chemotherapy in patients with advanced gastric and GE junction cancers.

Treatment Guidelines

The management of gastric cancer requires the expertise of several disciplines (radiation oncology, surgical oncology, medical oncology, nutritional support, and endoscopic expertise). Hence, the panel believes that multidisciplinary evaluation is preferred for the treatment



of patients with esophagogastric cancer particularly for loco-regionally confined tumors. The guidelines have now included a section on Principles of Multidisciplinary Team Approach for Gastroesophageal Cancers ([GAST-A](#)).

Workup

In patients with gastric cancer, symptoms can include anemia, early satiety, weight loss, nausea/vomiting, and/or bleeding. Newly diagnosed patients should undergo a complete history & physical examination (H&P), chest imaging, and endoscopy of the entire upper GI tract. A complete blood count (CBC), chemistry profile and abdominal CT with contrast should be performed. A pelvic CT scan or ultrasound is also recommended for women. EUS is recommended in patients with potentially resectable cancer. The panel also recommends H. pylori testing and appropriate treatment when clinically indicated.¹⁴⁴

The use of PET-CT scans is optional. PET-CT scans are useful for predicting response to preoperative chemotherapy as well as in the evaluation of recurrent gastric cancer.^{145, 146} They may also be useful in demonstrating occult metastatic disease, although there may be false positive results. Therefore, histologic confirmation of occult PET-avid metastasis is recommended.¹⁴⁷ Additional studies are needed to assess the efficacy of combined PET-CT scan in gastric cancer.

Initial workup enables patients to be classified into three groups with the following characteristics ([GAST-1](#)):

- Localized (Tis or T1a) cancer
- Locoregional cancer (stages I-III or M0)
- Metastatic cancer (stage IV or M1)

Patients with apparent locoregional cancer are further classified into the following groups:

- Medically fit patients (who are able to tolerate major abdominal surgery) with potentially resectable disease
- Medically fit patients with unresectable disease
- Medically unfit patients

Primary Treatment

EMR or surgery is the primary treatment option for medically fit patients with Tis or T1a tumors. Surgery is the primary treatment option for medically fit patients with potentially resectable locoregional cancer (T1b). For more advanced tumors, based on the results of the MAGIC trial, the guidelines have included perioperative chemotherapy with ECF regimen or its modifications with a category 1 recommendation for patients with T2 or higher tumors. This strategy is feasible in the institutions where a multi-disciplinary approach to localized gastric cancer is already in place. The panel has also included preoperative chemoradiation (cisplatin or paclitaxel or docetaxel in combination with 5-fluorouracil or capecitabine)^{73, 74} as an alternate treatment option with a category 2B recommendation.

RT (45-50.4 Gy) with concurrent fluoropyrimidine-based radiosensitization (category 1) is recommended for medically fit patients with unresectable locoregional cancer as well as medically unfit patients with locoregional cancer.^{67, 68} Palliative chemotherapy for metastatic or locally advanced cancer is an alternate option for this group of patients.

All patients diagnosed with metastatic disease after laparoscopic staging should be treated with any one of the regimens for metastatic or locally advanced cancer.

Medically unfit patients as well as medically fit patients with unresectable disease should undergo restaging (including CBC and chemistry profile, chest imaging, abdominal CT with contrast, pelvic imaging for women and PET-CT scan after completion of primary treatment. If there is a complete response, patients should be observed or they can undergo surgery if it is deemed appropriate. If there is evidence of residual, unresectable, locoregional and/or distant metastases, patients may be offered palliative treatment.

Postoperative Treatment

Postoperative treatment is based on the surgical margins and nodal status. Based on the results of the Intergroup trial (INT-0116), selected patients with no residual disease at surgical margins (R0 resection) and no evidence of metastases after gastrectomy may receive postoperative chemoradiation.⁷⁸ However, after R0 resection, patients with Tis or T1, N0 or T2, N0 tumors may be observed.

Fluoropyrimidine-based postoperative chemoradiation is recommended after R0 resection for selected patients with T2, N0 tumors along with high risk features such as poorly differentiated or higher grade cancer, lymphovascular invasion, neural invasion, or age younger than 50 years. INT-0116 trial also included patients (20%) with GE junction adenocarcinoma. Therefore, fluoropyrimidine-based postoperative chemoradiation may also be recommended (category 1) for patients with GE junction adenocarcinoma.

The panel recommends that all patients with T3, T4, or any node positive tumors with no residual disease at surgical margins (R0 resection) and all patients with microscopic residual disease at surgical margins (R1 resection) should be treated with RT (45-50.4 Gy) and concurrent fluoropyrimidine-based radiosensitization plus 5-fluorouracil (with or without leucovorin) or capecitabine. In the absence of

metastases (M1), patients with macroscopic residual disease at surgical margins (R2 resections) may be treated with RT (45-50.4 Gy) and concurrent fluoropyrimidine-based radiosensitization or palliative chemotherapy. Best supportive care may be offered for patients with poor performance status.

Follow-up and Surveillance

All patients should be followed up systematically. Follow-up should include a complete history and physical examination every 3-6 months for 1-3 years, every 6 months for 3-5 years and annually thereafter. CBC, chemistry profile, imaging studies or endoscopy should be done if clinically indicated. Patients who have undergone surgical resection should be monitored and treated as indicated for vitamin B₁₂ and iron deficiency.

Palliative Treatment for Recurrent or Metastatic disease

In a randomized comparison between chemotherapy and best supportive care vs. best supportive care alone for advanced gastric cancer, OS (8 months vs. 5 months, though not statistically significant) and time to progression (5 months vs. 2 months) were longer in patients receiving chemotherapy.¹⁴⁸ More patients in the chemotherapy group (45%) had an improved or prolonged high quality of life for a minimum of 4 months compared to those who received only best supportive care (20%). Recent meta-analysis of randomized trials that compared chemotherapy and supportive care in patients with advanced gastric cancer also showed that chemotherapy increased one year survival rate and improved in quality of life.¹⁴⁹ A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) comparing irinotecan to best supportive care in the second-line setting showed that irinotecan significantly prolonged OS compared to best

supportive care.¹⁵⁰ Median survival was 123 days in the irinotecan arm compared to 72.5 days in the best supportive care only arm.

Best supportive care is always indicated for patients with advanced gastric cancer. The decision to offer best supportive care alone or with chemotherapy is dependent on the patient's performance status. Several scales are available to measure performance status in patients with cancer. Karnofsky scale of Performance Status (KPS) and Eastern Cooperative Group Performance Status (ECOG PS) are the two commonly used scales.¹⁵¹⁻¹⁵³ KPS is an ordered scale with 11 levels (0 to 100) and the general functioning and survival of a patient is assessed based on their health status (activity, work and self-care). Low Karnofsky scores are associated with poor survival and serious illnesses (<http://www.hospicepatients.org/karnofsky.html>). ECOG PS is a 5-point scale (0-4) based on the level of symptom interference with normal activity. Patients with higher levels are considered to have poor performance status (http://www.ecog.org/general/perf_stat.html).

Palliative treatment options include chemotherapy, or clinical trial or best supportive care. Patients with a Karnofsky performance score of 60 or less or an ECOG performance score of 3 or more should probably be offered best supportive care only. Patients with better performance status (Karnofsky performance score of 60 or more, or an ECOG performance score of 2 or less) may be offered best supportive care with or without chemotherapy, or a clinical trial.

For metastatic gastric cancer, there have been a number of phase III trials that assessed combinations such as ECF, DCF, and FOLFIRI. There is no established second-line treatment for advanced gastric cancer. Some of the regimens listed in the guidelines are based on institutional preferences that have support only from phase II studies.

The following regimens are listed in the guidelines for metastatic or locally advanced cancer:

- DCF or its modifications
- ECF or its modifications
- Irinotecan in combination with cisplatin or fluoropyrimidine (5-fluorouracil or capecitabine)
- Oxaliplatin in combination with fluoropyrimidine (5-fluorouracil or capecitabine)
- Paclitaxel-based regimens
- Trastuzumab in combination with chemotherapy for patients with advanced gastric cancer or GE junction adenocarcinoma that is HER-2 –positive as determined by a standardized method.¹³⁴

The ECF regimen or its modifications and the DCF regimen have a category 1 recommendation. DCF modifications and all other regimens have a category 2B recommendation. Leucovorin can be used with certain infusional 5-fluorouracil-based regimens.

Best Supportive Care

The goal of best supportive care is to prevent, reduce, and relieve suffering, and improve quality of life for patients and their caregivers, regardless of disease stage. In patients with unresectable or locally advanced cancer, palliative interventions undertaken to relieve major symptoms may result in prolongation of life.

Bleeding

Bleeding is common in patients with gastric cancer and may be secondary to tumor or tumor related phenomenon, or as a consequence of therapy. A multidisciplinary approach is required for the proper diagnosis and management of gastrointestinal bleeding in

patients with cancer.¹⁵⁴ Patients with acute bleeding (hematemesis or melena) should undergo prompt endoscopic assessment. Angiographic embolization techniques may be useful in those situations where endoscopy is not helpful. External beam RT and/or endoscopic treatment may be indicated in patients experiencing bleeding.¹⁵⁵

Obstruction

Gastrojejunostomy is the most commonly used palliative treatment modality for malignant gastric outlet obstruction. Endoscopic placement of self-expanding metal stents (SEMS) is a safe, effective and minimally invasive palliative treatment for patients with luminal obstruction due to advanced gastric cancer.¹⁵⁶⁻¹⁵⁸ The results of a systematic review suggest that stent placement may be associated with more favorable results in patients with a relatively short life expectancy, whereas gastrojejunostomy is preferable in patients with a more prolonged prognosis.¹⁵⁹ Other palliative procedures such as external beam RT or balloon dilation may be used to alleviate symptoms of obstruction. The optimal palliative treatment for patients with malignant gastric outlet obstruction needs to be determined in large randomized clinical trials.

If endoscopic lumen restoration is not undertaken or unsuccessful, percutaneous endoscopic gastrotomy for gastric decompression may be performed if tumor location permits. Surgical placement of jejunal feeding tube may be necessary to provide adequate hydration and nutritional support. Nutritional counseling may also be valuable.

Pain

Pain control may be achieved with the use of RT and pain medications. If the patient is experiencing tumor related pain, then pain should be assessed and treated according to the NCCN Adult Cancer Pain guidelines. Severe uncontrolled pain following gastric stent placement

should be treated emergently with endoscopic removal of the stent once uncontrollable nature of pain is established.

Nausea/Vomiting

Patients experiencing nausea and vomiting should be treated according to the NCCN Antiemesis guidelines.

Summary

Gastric cancer is rampant in several countries around the world. Its incidence in the Western Hemisphere has been on the decline for more than 40 years. In the past 15 years, the incidence of proximal gastric cancer has increased in Western countries compared to non-proximal gastric cancer, which is more prevalent in Japan and other parts of the world. Diffuse histology is also more common now than intestinal type of histology. H. pylori infection, smoking, and high salt intake are the risk factors for gastric cancer. Few gastric cancers are associated with inherited gastric cancer predisposition syndromes.

Several advances have been made in therapeutic approaches, imaging techniques and staging procedures. Multidisciplinary team management is essential for treating patients with gastric cancer. Patients with locoregional disease should be referred to high volume treatment centers.

Surgery is the primary treatment option for medically fit patients with resectable gastric cancer. However in the West, surgery alone is an insufficient therapy for most patients. Subtotal gastrectomy is preferred for distal gastric cancers whereas proximal or total gastrectomy is recommended for proximal tumors. Based on the results of recent clinical trials, perioperative chemotherapy with the ECF regimen or its modifications is recommended for medically fit patients with resectable locoregional distal esophageal, GE junction and gastric



adenocarcinoma (category 1). Preoperative chemoradiation may also be considered for these patients (category 2B). Postoperative treatment is based on surgical margins and nodal status. All patients with unresectable disease may be treated with 5-fluorouracil-based chemoradiation.

Targeted therapies in combination with chemotherapy have produced encouraging results in the treatment of patients with advanced gastric, esophageal and gastroesophageal junction cancers. Based on the results of the ToGA trial, the NCCN panel included trastuzumab plus chemotherapy in the guidelines as a new treatment option for patients with HER2-positive advanced gastric cancer or GE junction adenocarcinoma. The efficacy vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) inhibitors in combination with chemotherapy for patients with advanced gastric and GE junction cancers are being evaluated in ongoing randomized phase III trials.

Best supportive care is an integral part of treatment, especially in patients with metastatic and advanced gastric cancer. Patients with good performance status can be treated with chemotherapy or best supportive care, whereas best supportive care alone is the appropriate treatment for patients with poor performance status.

Assessment of severity of the disease and related symptoms is essential to initiate appropriate palliative interventions that will prevent and relieve suffering and improve quality of life for patients and their caregivers. Treatment options used for palliation of symptoms in patients with advanced gastric cancer include endoscopic placement of SEMS, laser surgery or RT.

The NCCN Gastric Cancer guidelines provide an evidence-based systematic approach to the management of gastric cancer in the United States. Many new chemotherapeutic agents, targeted therapies, vaccines, gene therapy, and antiangiogenic agents are being studied in clinical trials. The panel encourages patients to participate in well-designed clinical trials to enable further advances.

Discussion
update in
progress

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19474385>.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *JAMA* 1991;265:1287-1289. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1995976>.
3. Johnston BJ, Reed PI. Changing pattern of oesophageal cancer in a general hospital in the UK. *Eur J Cancer Prev* 1991;1:23-25. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1842678>.
4. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. *Br J Cancer* 1990;62:440-443. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2206952>.
5. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006;24:2137-2150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16682732>.
6. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. *Semin Oncol* 2004;31:450-464. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297938>.
7. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. *Cancer* 2002;95:2096-2102. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12412162>.
8. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. *Int J Cancer* 2002;102:422-427. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12402314>.
9. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. *Int J Epidemiol* 2001;30:1415-1425. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11821356>.
10. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. *IARC Sci Publ* 1992:45-173. Available at:
11. Fitzgerald RC, Caldas C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. *Gut* 2004;53:775-778. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15138199>.
12. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. *N Engl J Med* 2001;344:1904-1909. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11419427>.
13. Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study in Surgery and Pathology (ed 12): Tokyo: Kanahara Shuppan; 1993.
14. Roder JD, Bottcher K, Busch R, et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. *Cancer* 1998;82:621-631. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9477092>.
15. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. *J Clin Oncol* 2004;22:2395-2403. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15197201>.
16. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. *Ann Surg* 2000;232:362-371. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10973386>.
17. Abdalla EK, Pisters PW. Staging and preoperative evaluation of upper gastrointestinal malignancies. *Semin Oncol* 2004;31:513-529. Available at:
18. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. *J Clin Oncol* 2007;25:2107-2116. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17513817>.
19. Weber WA, Ott K. Imaging of esophageal and gastric cancer. *Semin Oncol* 2004;31:530-541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297944>.
20. Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. *Eur J Nucl Med Mol Imaging* 2003;30:288-295. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12552348>.

21. Chen J, Cheong J-H, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. *Cancer* 2005;103:2383-2390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15856477>.
22. Rosenbaum SJ, Stergar H, Antoch G, et al. Staging and follow-up of gastrointestinal tumors with PET/CT. *Abdom Imaging* 2006;31:25-35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16333707>.
23. Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. *Eur J Surg Oncol* 2009;35:449-455. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19147324>.
24. Lim JS, Yun MJ, Kim M-J, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. *Radiographics* 2006;26:143-156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16418249>.
25. Matsumoto Y, Yanai H, Tokiyama H, et al. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. *J Gastroenterol* 2000;35:326-331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10832666>.
26. Tsenduren T, Jun S-M, Mian X-H. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. *World J Gastroenterol* 2006;12:43-47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16440415>.
27. Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. *Am J Surg* 2006;191:134-138. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16399124>.
28. Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. *Ann Surg Oncol* 2005;12:347-353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15915368>.
29. Burke EC, Karpeh MS, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. *Ann Surg Oncol* 1998;5:411-415. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9718170>.
30. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. *J Natl Cancer Inst* 1993;85:1839-1844. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8230264>.
31. Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. *J Clin Oncol* 1992;10:1933-1942. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1453207>.
32. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. *Semin Surg Oncol* 1994;10:12-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8115781>.
33. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. *Ann Surg* 1999;230:170-178. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10450730>.
34. Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? *J Am Coll Surg* 2004;199:880-886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15555971>.
35. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559-563. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16607678>.
36. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. *Jpn J Surg* 1981;11:127-139. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7300058>.
37. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol* 2007;14:317-328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17094022>.
38. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. *J Clin Oncol* 2004;22:2767-2773. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15199090>.

39. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008;359:453-462. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18669424>.
40. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999;340:908-914. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10089184>.
41. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 1999;79:1522-1530. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10188901>.
42. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol* 2004;22:2069-2077. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15082726>.
43. McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. *Cochrane Database Syst Rev* 2004. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15495024>.
44. Mansfield PF. Lymphadenectomy for gastric cancer. *J Clin Oncol* 2004;22:2759-2761. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15199086>.
45. Douglass HO, Hundahl SA, Macdonald JS, Khatri VP. Gastric cancer: D2 dissection or low Maruyama Index-based surgery--a debate. *Surg Oncol Clin N Am* 2007;16:133-155. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17336241>.
46. Jansen EPM, Boot H, Verheij M, van de Velde CJH. Optimal locoregional treatment in gastric cancer. *J Clin Oncol* 2005;23:4509-4517. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16002841>.
47. Khatri VP, Douglass HO. D2.5 dissection for gastric carcinoma. *Arch Surg* 2004;139:662-669. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15197096>.
48. van de Velde CJ, Peeters KC. The gastric cancer treatment controversy. *J Clin Oncol* 2003;21:2234-2236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12805321>.
49. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. *Eur J Surg Oncol* 2004;30:303-308. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15028313>.
50. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. *Br J Cancer* 2004;90:1727-1732. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15150592>.
51. Jatzko GR, Lisborg PH, Denk H, et al. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. *Cancer* 1995;76:1302-1312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8620402>.
52. Sierra A, Regueira FM, Hernandez-Lizoain JL, et al. Role of the extended lymphadenectomy in gastric cancer surgery: experience in a single institution. *Ann Surg Oncol* 2003;10:219-226. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12679305>.
53. Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. *Ann Surg* 2007;245:426-434. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17435550>.
54. Hull MJ, Mino-Kenudson M, Nishioka NS, et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. *Am J Surg Pathol* 2006;30:114-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16330950>.
55. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. *J Clin Oncol* 2005;23:4490-4498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16002839>.
56. Kooby DA, Suriawinata A, Klimstra DS, et al. Biologic predictors of survival in node-negative gastric cancer. *Ann Surg* 2003;237:828-835. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12796579>.
57. Bonenkamp JJ, van de Velde CJ, Kampschoer GH, et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. *World J Surg* 1993;17:410-414. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8337889>.

58. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001;48:225-229. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11156645>.
59. Hyung WJ, Cheong JH, Kim J, et al. Application of minimally invasive treatment for early gastric cancer. *J Surg Oncol* 2004;85:181-185. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14991872>.
60. Reyes CD, Weber KJ, Gagner M, Divino CM. Laparoscopic vs open gastrectomy. A retrospective review. *Surg Endosc* 2001;15:928-931. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11605108>.
61. Huscher CGS, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. *Ann Surg* 2005;241:232-237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15650632>.
62. Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. *Int J Radiat Oncol Biol Phys* 2002;52:283-293. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11872272>.
63. Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. *Int J Radiat Oncol Biol Phys* 1998;42:929-934. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9869212>.
64. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. *Lancet* 1994;343:1309-1312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7910321>.
65. Valentini V, Cellini F, Minsky BD, et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. *Radiother Oncol* 2009;92:176-183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19586672>.
66. Hazard L, O'Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. *World J Gastroenterol* 2006;12:1511-1520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16570342>.
67. Moertel CG, Childs DS, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. *Lancet* 1969;2:865-867. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4186452>.
68. The concept of locally advanced gastric cancer. Effect of treatment on outcome. The Gastrointestinal Tumor Study Group. *Cancer* 1990;66:2324-2330. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1700927>.
69. Milano MT, Garofalo MC, Chmura SJ, et al. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. *Br J Radiol* 2006;79:497-503. Available at: <http://bjr.birjournals.org/cgi/content/abstract/79/942/497>.
70. Lowy AM, Feig BW, Janjan N, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. *Ann Surg Oncol* 2001;8:519-524. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11456051>.
71. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. *J Clin Oncol* 2005;23:1237-1244. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15718321>.
72. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. *J Clin Oncol* 2004;22:2774-2780. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15254045>.
73. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953-3958. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16921048>.
74. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol* 2009;27:851-856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19139439>.
75. Baeza MR, Giannini TO, Rivera SR, et al. Adjuvant radiochemotherapy in the treatment of completely resected, locally advanced gastric cancer. *Int J Radiat Oncol Biol Phys* 2001;50:645-650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11395231>.

76. Dent DM, Werner ID, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. *Cancer* 1979;44:385-391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/113074>.
77. Moertel CG, Childs DS, O'Fallon JR, et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. *J Clin Oncol* 1984;2:1249-1254. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6491703>.
78. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725-730. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11547741>.
79. Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). *J Clin Oncol (Meeting Abstracts)* 2009;27:4515-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4515>.
80. Lee J, Kang W, Lim D, et al. Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. *J Clin Oncol (Meeting Abstracts)* 2009;27:4537-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4537>.
81. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16822992>.
82. Maehara Y. S-1 in gastric cancer: a comprehensive review. *Gastric Cancer* 2003;6 Suppl 1:2-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12775012>.
83. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357:1810-1820. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17978289>.
84. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. *Gastric Cancer Surgical Study Group. Lancet* 1999;354:273-277. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10440302>.
85. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 2005;23:5660-5667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16110025>.
86. Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. *Semin Oncol* 2004;31:574-587. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15297948>.
87. Bugat R. Irinotecan in the treatment of gastric cancer. *Ann Oncol* 2003;14 Suppl 2:ii37-40. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12810456>.
88. Einzig AI, Lipsitz S, Wiernik PH, Benson AB, 3rd. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. *Invest New Drugs* 1995;13:223-227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8729950>.
89. Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. *Am J Clin Oncol* 1998;21:416-419. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9708646>.
90. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. *Cancer J Sci Am* 1998;4:269-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9689986>.
91. Kim YH, Shin SW, Kim BS, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. *Cancer* 1999;85:295-301. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10023695>.
92. Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. *Expert Opin Pharmacother* 2006;7:1627-1631. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16872265>.
93. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. *EORTC*

Early Clinical Trials Group. Br J Cancer 1994;70:380-383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7914428>.

94. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-306. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10811496>.

95. Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am 1999;5:112-114. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10198733>.

96. Al-Batran S-E, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14966088>.

97. Louvet C, Andre T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12454110>.

98. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 1998;16:2877-2885. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9704742>.

99. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004;22:4319-4328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15514373>.

100. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10458249>.

101. Brell JM, Krishnamurthi SS, Javle M, et al. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol 2009;63:851-857. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18670776>.

102. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450-1457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18558665>.

103. Enzinger PC, Ryan DP, Clark JW, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009;20:475-480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19139178>.

104. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005;92:2122-2128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15942629>.

105. Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21:71-77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19605504>.

106. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15:1773-1781. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15550582>.

107. Moehler M, Haas U, Siebler J, et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003;14:645-650. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14501387>.

108. Ajani JA, Baker J, Pisters PWT, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002;94:641-646. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11857295>.

109. Glimelius B, Hoffman K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

- Ann Oncol 1994;5:189-190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8186165>.
110. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7533517>.
111. MacDonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-536. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7436184>.
112. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2579257>.
113. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2016625>.
114. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8996151>.
115. Vanhoefler U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-2657. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10894863>.
116. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11956258>.
117. Al-Batran S-E, Hartmann JT, Probst S, et al. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18349393>.
118. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17075117>.
119. Moehler MH, Thuss-Patience P, Arnold D, et al. Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group. J Clin Oncol (Meeting Abstracts) 2009;27:4554-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4554>.
120. Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: Preliminary results of a phase II study. Gastrointestinal Cancers Symposium; 2009:Abstract 47. Available at: 121. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006;107:221-231. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16770784>.
122. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18172173>.
123. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19153121>.

124. Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. *Ann Oncol* 2009;20:1529-1534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19474114>.
125. Takahashi I, Kakeji Y, Emi Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects. *Gastric Cancer* 2003;6 Suppl 1:28-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12775017>.
126. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. *Br J Cancer* 2003;89:2207-2212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14676796>.
127. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. *Oncology* 2000;58:191-197. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10765119>.
128. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* 2008;9:215-221. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18282805>.
129. Ajani JA, Lee F-C, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. *J Clin Oncol* 2006;24:663-667. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16446338>.
130. Lenz H-J, Lee F-C, Haller DG, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. *Cancer* 2007;109:33-40. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17133415>.
131. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. *J Clin Oncol (Meeting Abstracts)* 2009;27:4511-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4511>.
132. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. *Ann Oncol* 2008;19:1523-1529. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18441328>.
133. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. *Curr Opin Oncol* 2009;21:381-385. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19412098>.
134. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. *J Clin Oncol* 2009;27:Abstract 4556. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4556>.
135. Enzinger PC, Ryan DP, Regan EM, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. *J Clin Oncol (Meeting Abstracts)* 2008;26:4552. Available at: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4552.
136. Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. *J Clin Oncol (Meeting Abstracts)* 2009;27:4512-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4512>.
137. Sun W, Powell ME, O'Dwyer P, et al. A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). *J Clin Oncol (Meeting Abstracts)* 2008;26:4535. Available at: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/4535.
138. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). *Ann Oncol* 2007;18:510-517. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17164226>.
139. Kanzler S, Trarbach T, Seufferlein T, et al. Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. *J Clin Oncol*

(Meeting Abstracts) 2009;27:4534-. Available at:

<http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4534>.

140. Javle MM, Yang G, Nwogu CE, et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. *Cancer Invest* 2009;27:193-200. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19235592>.

141. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). *Br J Cancer* 2009;101:1261-1268. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19773760>.

142. Woell E, Greil R, Eisterer W, et al. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). *J Clin Oncol (Meeting Abstracts)* 2009;27:4538-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4538>.

143. X Zhang, J Xu, I Shen, et al. A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer. *Gastrointestinal Cancers Symposium 2009:LBA39*. Available at:

144. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007;102:1808-1825. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17608775>.

145. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. *Clin Radiol* 2003;58:215-221. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12639527>.

146. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. *J Clin Oncol* 2003;21:4604-4610. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14673049>.

147. Tian J, Chen L, Wei B, et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies. *Nucl Med Commun* 2004;25:825-831. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15266178>.

148. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. *Ann Oncol* 1997;8:163-168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9093725>.

149. Casaretto L, Sousa PLR, Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. *Braz J Med Biol Res* 2006;39:431-440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16612465>.

150. Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *J Clin Oncol (Meeting Abstracts)* 2009;27:4540-. Available at: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4540>.

151. Karnofsky DA, Burchenal JH. *The Clinical Evaluation of Chemotherapeutic Agents in Cancer*. In: MacLeod CM, ed. *Evaluation of Chemotherapeutic Agents*. New York: Columbia University Press; 1949:199-205.

152. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649-655. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7165009>.

153. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. *J Clin Oncol* 1984;2:187-193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6699671>.

154. Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. *J Support Oncol* 2005;3:101-110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15796441>.

155. Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. *Acta Oncol* 2008;47:421-427. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17899453>.

156. Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? *Gastrointest Endosc* 2004;60:1010-1017. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15605026>.



157. Lindsay JO, Andreyev HJN, Vlavianos P, Westaby D. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass. *Aliment Pharmacol Ther* 2004;19:901-905. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15080851>.

158. Kim TO, Kang DH, Kim GH, et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. *World J Gastroenterol* 2007;13:916-920. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17352023>.

159. Jeurnink SM, van Eijck CHJ, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. *BMC Gastroenterol* 2007;7:18-18. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17559659>.

A large, light gray watermark is centered on the page. It consists of two concentric circles. Inside the circles, the text "Discussion update in progress" is written in a large, sans-serif font, stacked in three lines: "Discussion", "update in", and "progress".

Discussion
update in
progress